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Mahfood: Sovaldi: The High Price for a Cure

Sovaldi: The High Price for a Cure
By Theresa C. Mahfood, J.D.
The Hepatitis C virus (HCV) is among the deadliest viruses in the world,
killing more Americans each day than the human immunodeficiency virus
(HIV), as well as sixty other infectious diseases, combined.1 Between 2.7
and 3.9 million people in the United States, 2 and seventy-one million people
worldwide, 3 live with chronic HCV, the most severe manifestation of the
disease.' The United States Department of Health and Human Services
reported that approximately 17,000 new cases of HCV infection occur in the
United States every year.'
6
Not all ethnic populations benefit from traditional HCV therapies;
however, advancements in pharmacogenetic research and curative,
personalized therapies such as Sovaldi,8 Harvoni, 9 and Epclusa deliver fewer

1. Hepatitis C Kills More Americans Than Any Other Infectious Disease, CTRS. FOR
DISEASE CONTROL & PREVENTION, https://www.cdc.gov/media/releases/2016/p0504-hepcmortality.html (last visited Dec. 5, 2017).
2. Hepatitis C FAQs for Health Professionals, CTRS. FOR DISEASE CONTROL &
PREVENTION, (Jan. 27,2017), https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm.
3. Hepatitis
C
Fact
Sheet,
WORLD
HEALTH
ORG.,
http://www.who.int/mediacentre/factsheets/fs 164/en/ (last updated July 2017).
4. Ann Pietrangelo, Hepatitis C by the Numbers: Facts, Stats, & You, HEALTHLINE,
https://www.healthline.com/health/hepatitis-c/facts-statistics-infographic#1 (last visited Dec.
5, 2017).
5. Office of Population Affairs, Hepatitis C, U.S. DEP'T HEALTH & HUM. SERVS,
https://www.hhs.gov/opa/reproductive-health/sexually-transmitted-infections/hepatitisc/index.html (last visited Dec. 5, 2017).
6. Brian L Pearlman, Hepatitis C Virus Infection in African Americans, 42 CLINICAL
INFECTIOUS
DISEASES
82,
84
(2006),
https://academic.oup.com/cid/article/42/1/82/397992/Hepatitis-C-Virus-Infection-inAfrican-Americans.

7. The term "curative" in this context is used only to indicate "non-detectable viral load."
In other words, the virus becomes non-detectable in the human body. My use of the term,
cure", throughout this article refers to treatments that have clinically been shown to be
curative in at least 90% of patients.
8. Sovaldi is the brand name for generic drug, Sofosbuvir. Hepatitis C Treatment
Factsheet Sofosbuvir (Sovaldi), INFOHEP, http://www.infohep.org/Hepatitis-C-treatmentfactsheet-Sofosbuvir-iSovaldiilpage/2845322/ (last visited Dec. 5, 2017).
9. Harvoni is the brand name for a Hepatitis C drug that combines sofosbuvir with
ledipasvir. It is primarily used to treat patients with Genotypes 1 and 4, whereas Sovaldi is
used to treat patients with Genotype 2. See infra Part 0 and accompanying notes; Harvoni vs
Sovaldi Or
is
Epclusa
The
New
Harvoni?,
HEPATITIS
C
SOCIETY,
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side effects, 10 greater barriers of resistance to HCV, and lower pill burdens
than their predecessors.11 Nevertheless, the high cost of HCV therapies,
particularly of Sovaldi, presents a purchasing barrier to the HCV patients who
stand to benefit the most.12 As such, health insurance companies are left to
pick up the slack.13 These high costs invite an ethical dilemma, questioning
the fairness of Sovaldi's price and how Sovaldi may be justly allocated."
Compounding this dilemma, many HCV patients experience economic
instability and are underinsured.15
Drawing upon public outrage over the high price of Sovaldi, the
Southeastern Pennsylvania Transit Authority (SEPTA) filed a class action
lawsuit in 2015, claiming that Sovaldi's manufacturer, Gilead Sciences
(Gilead), engaged in unlawfully exorbitant pricing schemes that make it
difficult for racial minority consumers and the federal government to afford
Sovaldi.16 SEPTA also claimed that Gilead violated the Patient Protection
and Affordable Care Act (ACA) by engaging in price discrimination against
disabled people.1 7 The District Court for Eastern Pennsylvania granted
Gilead's motion to dismiss, holding that an individual's mere diagnosis of
Hepatitis C does not constitute a disability.18 Furthermore, the District Court
found that evidence of Gilead's high prices for Hepatitis C drugs, in light of
certain ethnic populations' higher frequency of Hepatitis C diagnoses, was

http://esofosbuvir.com/harvoni-medicine-even-better-sovaldi/harvoni-vs-sovaldi! (last visited
Dec. 5, 2017) [hereinafter, Harvoni vs Sovaldi].
10.
Epclusa, which is mainly used to treat patients with Genotype 3, combines sofosbuvir
and velpatasvir. See Harvoni vs Sovaldi, supra note 9; How come generic Epclusa can cost
less than $1,000, HEPATITIS C SOCIETY, http://esofosbuvir.com/generic-epclusa-sofosvelindias-generics/ (last visited Nov. 14, 2017).
11.
Sovaldi, Harvoni, and Epclusa work according to the same biochemical mechanisms.
Since Sofosbuvir (Sovaldi) is a component of both Harvoni and Epclusa, to simplify, I will
only reference Sovaldi for the remainder of this paper.
12.
See Bruce Japsen, At $1,000 A Pill, Hepatitis C Drug Sovaldi Rattles Medicaid
Programs,
FORBES
(Apr.
28,
2014
8:00
AM),
https://www.forbes.com/sites/brucejapsen/2014/04/28/pricey-hepatitis-pill-sovaldi-rattlesmedicaid-programs/#4c3ca4446efe.
13.
Id.
14.
Id.
15.
Id.
16.
Pa. Transp. Auth. v. Gilead Sci., Inc., 102 F. Supp. 3d 688, 693-94 (E.D. Pa. 2015).
17.
Id.; Allissa Wickham, PA TransitAgency Slaps Gileadwith Price Gouging Suit, LAW
360 (Dec. 11, 2014, 5:38 PM) https://www.law360.com/articles/603544/pa-transit-agencyslaps-gilead-with-price-gouging-suit (explaining that SEPTA's claim that Gilead engaged in
price discrimination against disabled people was based on SETPA's argument that Gilead
caused the plaintiffs to be "excluded from a health activity that receives federal funds" based
on their hepatitis C disability).
18.
Pa. Transp. Auth., 102 F. Supp. at 700 (distinguishing between allegations of a mere
diagnosis of Hepatitis C and an actual "disability" which is a "physical or mental impairment
that substantially limits one or more major life activities."); 29 U.S.C. § 705(20)(B); 42 U.S.C.
§ 12102 (1)(A).
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altogether insufficient to support a claim that Gilead discriminated on the
basis of race.19
Ultimately, the court dismissed all ACA-related
discrimination claims against Gilead.2" Additionally, the court rejected the
plaintiffs' attempt to invoke state law to challenge Gilead's pricing scheme
for its patent-protected drugs.2 1

Although the court's final disposition did not favor SEPTA,22 the lawsuit
reflects the attitudes of millions of Americans towards pharmaceutical
manufacturers who develop and set high prices for new drugs.23 While the
legal issues outlined by SEPTA's class action lawsuit surpass the scope of
this paper, this paper uses Sovaldi as a foundation for important ethical
analyses pertaining to drug prices, the motivations of pharmaceutical
companies, and public allocation of expensive drugs.

19. Pa. Transp. Auth., 102 F. Supp. at 701.
20. The plaintiffs in SEPTA v. Gilead argued that Gilead's pricing violated the
Rehabilitation Act and the Civil Rights Act by discriminating against disabled persons and
disparately impacting minorities, although they admitted the pricing may not have been
intentionally discriminatory. See Id. at 697-99, 702 (rejecting plaintiffs' arguments that
Gilead's pricing violated the Rehabilitation Act and the Civil Rights Act by discriminating
against disabled persons and disparately impacting minorities); see also Nondiscrimination
provisions of the ACA at 42 U.S.C. § 18116 (2010) (prohibiting any health program or activity
receiving federal funding from excluding from participation, denying benefits to, or otherwise
discriminating against any individual on the grounds of race, color, national origin sex, age,
and disability).
21.
Pa. Transp. Auth., 102 F. Supp. at 702-08 (finding that: .to the extent that plaintiffs
seek to use state law to challenge Gilead's exercise of its exclusive patent rights to make
pricing decisions, plaintiffs' claims are preempted. Federal patent law contemplates the
tradeoffs between exclusivity and access, and plaintiffs cannot use state law to adjust that
balance by forcing Gilead to lower its prices or disgorge profits from the sale of its patented
drugs ... plaintiffs plead no facts to suggest or raise the inference that Gilead has used pricing
discretion within its contracts to provide Sovaldi and Harvoni, or that SEPTA or another
member of the putative class has been on the receiving end of unfair or bad faith dealing by
Gilead pursuant to any discretion Gilead may have in a contract with it or another party...
plaintiffs simply cannot invoke state law to challenge Gilead's overall pricing scheme for its
patented drugs.").
22. Id. at 708; See e.g., Ed Silverman, Lawsuit Alleges Price Gouging by Maker of
Hepatitis
Drug,
WALL
ST.
J.
(Dec.
18,
2014,
10:50
PM),
https://www.wsj.com/articles/lawsuit-alleges-price-gouging-by-maker-of-hepatitis-drug1418961024 [hereinafter, LawsuitAlleges Price Gouging] (citing experts, including Professor
C. Scott Hemphill, a Columbia Law School professor, who viewed SEPTA's antitrust claim
as meritless because "having a monopoly and setting high prices do not violate antitrust law.").
23.
See, e.g., Poll: Majorities of Democrats, Republicans and Independents Support
Actions to Lower Drug Costs, Including Allowing Americans to Buy Drugsfrom Canada, THE
HENRY J. KAISER FAM. FOUND. (May 1, 2017), http://www.kff.org/health-costs/pressrelease/poll-majorities-of-democrats-republicans-and-independents-support-actions-tolower-drug-costs-including-allowing-americans-to-buy-drugs-fromcanada/?utm campaign=KFF-2017-May-Poll-Lower-Drug-Costs;
Poll: Americans want
government to bring down prescription drug prices, CBS (Aug. 20, 2015),
https://www.cbsnews.com/news/poll-americans-want-government-to-bring-downprescription-drug-prices/.
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This paper concludes that there is insubstantial evidence proving that
Gilead behaved unethically by setting the price of Sovaldi at $1,000 per pill.
The price may be deemed reasonable due to:
(1) Sovaldi's superior quality and curative nature;
(2) the high costs incurred by drug developers and manufacturers and the
need to recoup those costs to continue developing new drugs;
(3) the complicated healthcare system and its patent laws which do not
restrict the prices drug manufacturers can set;
(4) trends in rising drug prices over the last two decades; and
(5) evidence that Gilead is supporting several altruistic patient support
24
programs to distribute Sovaldi to millions of people free of charge.
Gilead seeks to recoup high enough profit margins to greatly expand its
research and development (R&D) to develop many new cures for diseases,
optimize benefits for future patients once the patent expires, and use a portion
of its revenue to provide drugs free of charge or at lower prices for patients
who cannot afford to pay the high price. 5
Therefore, despite opposing
arguments, there is evidence that Gilead's ethical interests are, in fact, just
and beneficent.
Part I of this paper provides an overview of Hepatitis C and why the
development of Sovaldi was revolutionary. Part II describes the history of
HCV treatment. Part III explains the development of Sovaldi and how Gilead
acquired rights to manufacture and distribute the drug. Part IV tackles the
ethical debate surrounding the Sovaldi controversy, and is divided into two
sections: A and B. Section A discusses whether American HCV patients
have a fundamental right to receive Sovaldi treatment. Section B describes
some of the barriers preventing many Americans from obtaining Sovaldi.26
Part V, across three sections, analyzes the ethics inherent in Gilead's
justification of Sovaldi's price. Specifically, section A determines whether
the quality of Sovaldi compared to competing HCV drugs is an ethical
justification for the drug's price. Section B discusses common trends in the
U.S. healthcare system that have contributed to the high prices of
pharmaceuticals. Section C, provides evidence that, contrary to popular
belief, Gilead's pricing decisions were not selfishly motivated.

24.
See, e.g., Sovaldi: Who's to Blame for the $1,000 a Day Cure?, KNOWLEDGE @
WHARTON (Apr. 16, 2014), http://knowledge.wharton.upenn.edu/article/sovaldi-whos-blame1000-day-cure [hereinafter, Sovaldi: Who's to Blame].
25.
See id.
26.
Probable solutions as to the issue of what action(s) could be taken, either by Gilead
or legislators to lower Sovaldi's price, are beyond the scope of this article.
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I.

THE HEPATITIS C INFECTION

HCV is a blood-borne, single stranded ribonucleic acid (RNA) virus that
almost exclusively infects and abundantly replicates within hepatocytes. 2
Chronic Hepatitis C infection is a severe disease that leads to liver cirrhosis
or liver cancer in a significant number of cases.28 Most people living with

chronic Hepatitis C infection are asymptomatic. 9
HCV is most commonly transmitted through unsafe needle injection
practices, inadequate sterilization of medical equipment, and the use of
unscreened blood and blood products.30 High-risk populations include: drug
users and people who share needles; children born from mothers infected by
HCV; anyone who received an organ transplant or blood transfusion before
1992; patients who have spent many years on kidney dialysis; people with
HCV-infected sex partners; and people with HIV infection.31 In the United
States, African Americans have a substantially higher rate of chronic
Hepatitis C infection than any other ethnic group.3 2 Today, there is no
vaccine to prevent Hepatitis C.33
Six distinct HCV genotypes with multiple subtypes have been identified
worldwide.34 In the U.S., genotype 1 is the most common, accounting for
close to seventy-five percent of all HCV patients, as well as the most resistant
to traditional standard therapies.3 However, the prevalence of genotype 1
among African Americans is ninety-one percent, compared to sixty-seven
percent among Caucasians.36 There is no scientific consensus that explains
the disparity among African Americans, and furthermore, African American
genotypes have exhibited resistance to traditional HCV therapies more than

27. David R. McGivern & Stanley M. Lemon, Virus-Specific Mechanisms of
Carcinogenesisin Hepatitis C Virus Associated Liver Cancer, 30 ONCOGENE 1969, 1971-72
(2011).
28. Id. at 1969.
29. Hepatitis C FAQs for the Public, CTRS. FOR DISEASE CONTROL & PREVENTION,

http://www.cdc.gov/hepatitis/hcv/cfaq.htm (last updated Oct. 17, 2016).
30.
31.
32.

Hepatitis C Fact Sheet, supra note 3.
Id.
Hepatitis C DisproportionatelyAffects the African American Community, CTRS. FOR
DISEASE CONTROL & PREVENTION, https://www.cdc.gov/hepatitis/blackhistmnth-hepc.htm

(last updated Feb. 1, 2017).
33.

Hepatitis C Fact Sheet, supra note 3.

34. Are There Different Types of Hepatitis C (Genotypes)?, HEPATITIS CENT.,
http://www.hepatitiscentral.com/hepatitis-c/ (last visited Dec. 5, 2017) ("A genotype is a
classification of a virus based on the genetic material in the Ribonucleic acid (RNA) strands
of the virus.").
35.

Alan Franciscus, African Americans and Hepatitis C, HCV ADVOCATE (Aug. 2016)

http://hcvadvocate.org/hepatitis/factsheets-pdf/AfricanAmericans.pdf

[hereinafter, African

Americans and Hepatitis C].
36. Id.
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Caucasian genotypes.
II.

THE HISTORY OF

HCV TREATMENT

Combination therapy prescribed by physicians, including pegylated
interferon-a (pegIFN) and ribavirin (RBV), has traditionally constituted the
standard of care for treating chronic Hepatitis C infection.3 8 Physicians most
commonly prescribed twelve to thirty-two weeks of an oral protease
inhibitor, twenty-four to forty-eight weeks of pegIFN, and RBV to patients
with HCV genotype 1, and twenty-four weeks of pegIFN to patients with
HCV genotypes 2 and 3.39 The duration of the therapy depended on each
individual patient's stage of liver fibrosis and overall response rates to the
treatment.4 0 However, pegIFN and RBV could not cure the Hepatitis C
infection, but merely prevent the infection from spreading, protecting the
remaining healthy cells; even so, these therapies were not necessarily
effective in treating patients with advanced liver disease. 1 One 2010 study
reported that, together, pegIFN and RBV were about fifty-four to sixty-three
percent effective in treating HCV. 42 Additionally, pegIFN and RBV were
ineffective in treating patients with HCV genotype 1, which affects seventy
to seventy-five percent of all HCV patients living in the United States. 3 HCV
patients of each genotype reported harsh side effects while using pegIFN and
RBV such as anemia, negative changes in thyroid function, low white blood
cell and platelet count, hyperglycemia, hair loss, psychiatric illness,
etcetera. 4 These disappointing outcomes were further exacerbated by the
potential for human error, as HCV patients must maintain a complicated pill

37.
38.

Pearlman, supra note 6, at 88.
Colleen M. Story, Hepatitis C Medications: Costs, Side Effects, and More,
HEALTHLINE (July 14, 2016) http://www.healthline.com/health/hepatitis-c-medications-costsside-effects-and-more#Traditionaldrugs2.
39.
Chronic HepatitisC Virus (HCV) Infection: Treatment Considerations,THE DEP'T OF
VETERANS AFFAIRS NAT'L HEPATITIS C RESOURCE CTR. PROGRAM & THE NAT'L VIRAL
HEPATITIS PROGRAM IN THE OFFICE OF PATIENT CARE SERVS., [hereinafter, Chronic Hepatitis
C Virus (HCV) Infection] https://www.hepatitis.va.gov/pdf/treatment-considerations-201603-28.pdf (last updated Mar. 28, 2016).
40.
Id. at 31.
41.
McGivern & Lemon, supra note 27, at 1969.
42.
Fernando L Goncales Jr. et al., Retreatment of Hepatitis C Patients with Pegylated
Interferon Combined with Ribavirin in Non-Responders to Interferon plus Ribavirin: Is it
different in Real life?, 10 BMC INFECTIOUS DISEASES 1, 2 (2010).
43.
Id. at 1; cf African Americans and Hepatitis C, supra note 35. (Again, this burden is
predominantly felt by African Americans, with 91% of infected African Americans possessing
genotype 1, compared with 67% of infected Caucasians).
44.
HCV Medications, Ribavirin (Copegus, Rebetol, Ribasphere), HEPATITIS C ONLINE,
https://www.hepatitisc.uw.edu/page/treatment/drugs/ribavirin-drug/prescribing-information
(last visited Dec. 5, 2017) (Other harsh side effects of Ribavirin include flu-like symptoms,
nausea, rash, vision problems, weight gain or loss, and insomnia.).
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regimen to comply with traditional combination therapies.45 Naturally, these
negatives marshalled scientific investigators' motivation to develop a less
burdensome and more efficacious HCV drug, with fewer side effects.46
Increasing advancements in the field of pharmacogenomics, particularly in
the wake of the Human Genome Project, inspired hope that a breakthrough
HCV therapy was within reach.4
III.

THE DEVELOPMENT OF SOVALDI

Since the Acquired Immune Deficiency Syndrome (AIDS) became a
widespread epidemic in the 1980s, the National Institutes of Health (NIH)
has invested aggressively in university-based scientific investigators.48
Specifically, the NIH provided large grants to build virology to foster the
discovery of AIDS therapies through clinical trials.4 9 In the 1990s, HCV
became a similarly-pursued "hot topic" among investigators and
pharmaceutical companies; as HCV and HIV share a similar structure, the
NIH also financed the genetic investigation of Hepatitis C.5"
One
investigator was Raymond Schinazi, Co-Director of the Virology and Drug
Discover Core at the Emory School of Medicine in Atlanta. 51 For over twenty
years, Schinazi received approximately $7.7 million from the National
Institute of Allergy and Infectious Diseases to conduct clinical research.52
Schinazi, aspiring to develop an antiviral drug for treating various strains of
hepatitis, formed the small pharmaceutical company, Pharmasset, in the late
1990s. 53 Pharmasset contained a library of inventive therapeutics to combat
Hepatitis C, which investigators hoped could unlock the mystery of how to
cure the disease.54 One of those molecules, PSI-7977 (Sofosbuvir),55 had first
45.
Id.
46.
Sarah Kliff, This Drug Costs $84,000, And There's Nothing the US Health-Care
System
Can
Do
to
Stop
It,
Vox
(Dec.
2,
2014)
https://www.vox.com/2014/12/2/7282833/sovaldi-cost.
47.
Chun-Hsiang Wang et al., Pharmacogenomicsof Chronic Hepatitis C Therapy with
Genome-wide Association Studies, 2 J. OFEXPERIMENTAL PHARMACOLOGY 73, 77 (2010).
48.
Merrill Goozner, Why Sovaldi Shouldn't Cost $84,000, MODERN HEALTHCARE (May
3, 2014), http://www.modemhealthcare.com/article/20140503/MAGAZINE/305039983.
49.
THE AIDS REs. PROGRAM OF THE NAT'L INSTS. OF HEALTH, 53-94 (1991).
50.
HIV and OpportunisticInfections, Coinfections, and Conditions:HIV and Hepatitis
C, DEP'T. OF HEALTH & HUMAN SERV., https://aidsinfo.nih.gov/understanding-hiv-aids/factsheets/26/88/hiv-and-hepatitis-c (last updated July 25, 2017).
51.
Raymond Schinazi, PhD, EMORY YERKES NAT'L PRIMATE RES. CTR.,

http://www.yerkes.emory.edu/research/divisions/emory-vaccine-center/schinazi-raymond.h
tml (last visited Dec. 5, 2017).

52.

Goozner, supra note 48.

53.
Sam Knight, Hepatitis C: The Cure?, FIN. TIMES (Mar. 15, 2013),
https://www.ft.com/content/542ad524-8b77-1 1e2-bla4-00l44feabdc0.
54.
Kliff, supra note 46.
55.
Knight, supranote 53. (PSI-7977 and sofosbuvir are synonyms for the same chemical
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been developed in the mid-2000s. 6 In what Schinazi described as "a
collision of science and serendipity," Pharmasett investigators realized that
Unlike compounds previouslySofosbuvir would surpass expectations.
tested, Sofosbuvir represented a breakthrough discovery that the medical
community would later deem a "cure" for Hepatitis C."
Other pharmaceutical companies learned of the revolutionary Sofosbuvir,
thus catalyzing a bidding war over which company would get the rights to
the drug. 9 In 2011, one of the world's largest Ameican-based
biopharmaceutical companies, Gilead, emerged triumphant, purchasing
Pharmasett and its holdings, including Sofosbuvir, for the steep price of $11.4
billion. 6' Gilead went on to spend tens of millions of dollars to complete
Sofosbuvir would eventually become
Sofosbuvir's clinical trials. 61
commonly known as its popular brand name, Sovaldi.62
Sovaldi works differently than previous Hepatitis C drugs.63 Previously,
existing HCV therapies did not work for all patients, and a treatment's
duration and success depended greatly on the individual patient's genotype.6 4
In contrast, Sovaldi combats HCV directly, targeting the virus' genetic
information (RNA), thus blocking the virus' ability to multiply in liver
cells.65 Phase III clinical trials demonstrated that combination therapy with
Sovaldi is effective for treating people with HCV genotype 1 66

compound. The most famous brand name this compound is sold under is Sovaldi).
56.
Kliff, supra note 46.
57.
Id.
58.
Knight, supra note 53.
59.
Kliff, supra note 46.

60.

Id.

61.
Goozner, supra note 48; see also, Safety Study of Regimens of Sofosbuvir, GS-0938,
and Ribavirin in Patients With Chronic Hepatitis C Infection (QUANTUM), U.S. NAT'L
LIBRARY OF MED., https://clinicaltrials.gov/ct2/show/NCT01435044 (last updated Feb 6,
2014).
62.
Kliff, supra note 46.
63.
Id.
64.
Kenneth Hirsch, Hepatitis C Genotype: Your QuestionsAnswered, HEALTHLINE (June
see also
15, 2017), https://www.healthline.com/health/hepatitis-c-genotype-expert#2;
Sofosbuvir

(Sovaldi),

HEPATITIS

C

ONLINE,

(last visited Dec. 5,
http://www.hepatitisc.uw.edu/page/treatment/drugs/sofosbuvir-drug
2017) (discussing HCV treatment based on genotype).
65.
Sovaldi (Sofosvubir,), supra note 64.
ADVOCATE
(2015),
66. Alan
Franciscus,
HCSP
Fact
Sheet,
HCV
http://hcvadvocate.org/hepatitis/factsheets-pdf/SovaldiGT2-3.pdf [hereinafter, HCSP Fact
Scheet]; see Combination Antiviral Therapy for Hepatitis C, WEBMD (June 4, 2014),
http://www.webmd.com/hepatitis/combination-antiviral-therapy-for-hepatitis-c (combination
therapy is a form of treatment in which a patient is given two or more drugs for a single
disease); see also Course Modules, Treatment of HCV Genotype 1, HEPATITIS C ONLINE,
https://www.hepatitisc.uw.edu/go/treatment-infection/treatment-genotype-1/core-concept/all
(last visited Dec. 5, 2017).
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IV. THE ETHICAL DEBATE SURROUNDING SOVALDI

The controversy over Sovaldi's price is rooted in ethical questions of
beneficence and social justice.6 It bears understanding these theories at
issue. The theory of beneficence obligates researchers to prioritize the
welfare of research participants in any clinical trial or research study. 68 Two
general rules direct this principle: (1) "do not harm;" and (2) "maximize
possible benefits and minimize possible harms. 6 9 Similarly, under John
Stuart Mill's theory of utilitarianism, the best action maximizes the wellbeing of sentient beings."v Clearly, beneficence and utilitarianism share the
tenets of maximizing benefits, as well as, by extension, minimizing harms."1
By contrast, Mill's interpretation of justice concerns with the moral duties
owed to people who have correlative rights. 2 Thus, followers of Mill's ideas
on utilitarianism would argue that justice is served most optimally when its
principles lead to positive consequences."v Drawing from principles of both
beneficence and utilitarianism, true social justice relies on the harmony
between economic and social welfare for true justice to exist."
Considering society's finite wealth and resources, the question becomes
how to most reasonably and optimally allocate benefits to members of
society. Both economic and social justice are necessary to properly address
this quandary. According to the Center for Economic and Social Justice,
"social justice" encompasses "economic justice. '' 7' Economic justice
involves "input, out-take, and feedback for restoring harmony or balance

67.
For the purposes of this paper, the terms "social justice" and "fairness" will be used
interchangeably.
68.
The Belmont Report, DEP'T OF HEALTH, EDUC., & WELFARE, U.S. DEP'T OF HEALTH
& HUMAN SERVS (Mar. 16, 2016), https://www.hhs.gov/ohrp/regulations-and-policy/belmontreport/index.html.
69.
Id.; see also The Principle of Beneficence in Applied Ethics, STANFORD
ENCYCLOPEDIA

OF

PHIL.

(Oct.

3, 2013),

http://plato.stanfordedu/entries/principle-

beneficence/#utithe.
70.
The Principle of Beneficence in Applied Ethics, supra note 69; see also John Stuart
Mills: Ethics, INTERNET ENCYCLOPEDIA OF PHIL., http://www.iep.utm.edu/mill-eth/#H9, (last
visited Dec. 5, 2017) (defining "utility," or "the only things desirable as ends" as the
"promotion of happiness" and the "freedom of pain.").
71.
The Principle of Beneficence in Applied Ethics, supra note 69; The Belmont Report,
supra note 68.
72.
John Stuart Mills: Ethics, supra note 70; Risk, STANFORD ENCYCLOPEDIA OF
PHILOSOPHY (Aug. 11, 2011), https://plato.stanford.edu/entries/risk/ ("duty not to harm other
people can be extended to a duty not to perform actions that increase their risk of being
harmed.").
73.
John StuartMills: Ethics, supra note 70.
74.
See The Belmont Report, supra note 68.
75.
Defining Economic Justice and Social Justice, CTR. FOR ECON. & SOC. JUSTICE,
http://www.cesj .org/learn/definitions/defining-economic-justice-and-social-justice/
(last
visited Dec. 5, 2017).
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between input and output."'7 6 Notable political economists Louis Kelso and
Mortimer Adler offer two additional essential and independent principles
required to attain economic justice: the principle of participation
(participative justice) and the principle of distribution (distributive justice).
Participative justice requires equal opportunity to both gain access to
private property in productive assets and engage in productive work. 8
Participative justice describes how a person makes "input" or contributes to
the economic process to make a living. Monopolies, special privileges, and
other exclusionary social barriers to economic self-reliance thus stand in
direct opposition to participative justice.80 However, participative justice
does not guarantee equal results.81 As long as society's institutions are
structured in ways that allow each person to contribute to the economy by
working and owning property, there is participative justice within that
society. The laws governing the U.S. economy and financial institutions
generally give each citizen the opportunity to participate in the economic
market through working and ownership.83 Inasmuch as the price of Sovaldi
is high, the principle of participative justice is satisfied in the U.S. 84
The concept of distributive justice suitably addresses the question of how
to most reasonably allocate benefits to members of society.8 5 More
specifically, distributive justice concerns the fair allocation of resources
among diverse members of a community and takes into account the
procedure, pattern, and goods portions of the distribution.8 6 Under this
concept, a person's rights to an economic system's "output" match his or her
labor and capital inputs.8 In a capitalistic society, distributive justice is
"automatically linked to participative justice, and incomes are linked to
productive contributions."88 Furthermore, contracts and property hold

76.

Id.

77. Louis 0. KELSO & MORTIER J.
Licensing, LLC 2011).
78.
79.

ADLER, THE CAPITALIST MANIFESTO 80-81

(Literary

Defining Economic Justice and Social Justice, supra note 75.
Id.

80. Id.
81.
Id.
82. Id.
83. See id.; see also U.S. CONST. amend. V (defining the right to property); see also Truax
v. Raich, 239 U.S. 33, 41 (1915) (stating "[t]he right to work for a living in the common
occupations of the community is of the essence of that personal freedom and opportunity
which it was the purpose of the [Fourteenth] Amendment to secure").
84. See U.S. CONST. amend. V; see Truax, 239 U.S. at 33; see Defining Economic Justice
and Social Justice, supra note 75.
85. Defining Economic Justice and Social Justice, supra note 75.
86. Id.
87. Id.
88. Id.
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important roles in society, which the principle of distributive justice aims to
protect by utilizing the free and open marketplace, rather than the
government, as the most democratic means of deciding just prices, wages,
and profits.8 9
The last principle of economic justice is social justice. The Oxford English
Dictionary defines social justice as: "[j]ustice in terms of the distribution of
wealth, opportunities, and privileges within a society." 9 The Center for
Economic and Social Justice takes this concept one step further, defining
social justice as "the 'feedback and corrective' principle that detects
distortions of the input and/or out-take principles, and guides the corrections
needed to restore a just and balanced economic order for all."9 1 Unjust
barriers to participation, such as monopolies, threaten this principle."
In summary, Kelso and Adler emphasize that the principles of
participative, distributive, and social justice must maintain an authoritative
function in society, otherwise economic justice will collapse.93 Therefore, a
drug like Sovaldi must be fairly allocated and unjust barriers to participation
in a competitive market must be eliminated in order for pure economic justice
to be served.94 The remainder of this paper will assess whether these
conditions hold true with respect to the distribution of Sovaldi.
A.

Do American HCV Patients Have a FundamentalRight to Receive
Sovaldi Treatment?

In light of Sovaldi's ability to "cure" chronic Hepatitis C when
administered in combination with other HCV therapies, 95 barriers to patients'
access to Sovaldi may be perceived as unfair. 96 Embedded in the American
justice paradigm is the notion that there are certain rights inherent to all
89.
Id.
90.
Social Justice, ENGLISH OXFORD LIVING DICTIONARIES (last visited Dec. 5, 2017)
https://en.oxforddictionaries.com/definition/social-justice.
91.
Defining Economic Justice and Social Justice, supra note 75.
92.
Id.
93.
Id.
94.
Id.
95.
See African Americans and Hepatitis C, supra note 35 (Sovaldi, in combination with
other HCV drugs, is said to have a high cure rate for patients.); see Brian L. Pearlman & Nomi
Traub, Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus
Infection:
A
Cure
and
So
Much
More,
52
CID
889
(2011),
https://academic.oup.com/cid/article/52/7/889/300592/Sustained-Virologic-Response-toAntiviral-Therapy ("Cure rates" are based on Sustained Virologic Response (SVR). The
medical community defines SVR as being free from detectable viruses in the blood plasma for
24 weeks after completion of antiviral therapy.).
96.
Susan Scutti, Will New Hepatitis C Guidelines From WHO Help Make Sovaldi And
Other New Drugs More Affordable?, MED. DAILY (Apr. 9, 2014, 1:56 PM),
http://www.medicaldaily.com/will-new-hepatitis-c-guidelines-who-help-make-sovaldi-andother-new-drugs-more-affordable-275594.
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human beings regardless of social status, race, ethnicity, gender, or national
origin.9 Indeed, as the Declaration of Independence enshrined, "We hold
these truths to be self-evident, that all men are created equal, that they are
endowed by their Creator with certain unalienable Rights, that among these
are Life, Liberty, and the pursuit of Happiness."9 8 Strikingly similar is the
Fourteenth Amendment, providing that no State shall deprive any person of
"life, liberty, or property" without due process of law.99 Clearly, the United
States has historically recognized life as an inalienable right, and a
fundamental right under the Fourteenth Amendment, to be protected both
universally and through jurisprudence. 0 0 Less clear is what the protection of
life actually entails. 0 1
Ethical, economic, and legal authorities grapple with the notion of an
inalienable right to life.10 2 Generally, a "right" is an entitlement to have or
obtain something or to be treated a certain way.103 Inalienable rights are
based on natural law, codes of morality, and ethical principles. 1" Even more,
inalienable rights are inherent of all individuals, and arguably fundamental in
nature. 1 5 Accordingly, inalienable rights receive a high degree of protection
against governmental encroachment, whereas the protections of strictly legal
rights may shift to reflect changing laws.10 6
While the "right to life" is fundamental, the "right to health care" does not
meet this threshold in the United States. Whether health care constitutes an
"inalienable right" or a privilege has been the crux of an ongoing, divisive
debate within the United States.10 7 In 2008, President Barack Obama opined
97.
See, e.g., THE DECLARATION OF INDEPENDENCE para. 2 (U.S. 1776).
98.
Id.
99.
U.S. CONST. amend. XIV, § 1.
100.
See generally Geoffrey R. Stone & William P. Marshall, The Framers' Constitution
Toward a Theory of Principled Constitutionalism, AM. CONST. Soc'Y FOR LAW AND POL'Y
(Sept.
2011),
https://www.acslaw.org/The%20Framers' %20Constitution%20%20Stone%20and%2OMarshall.pdf (that the judicial system plays a big role in constitutional

interpretation).
101.
Id. (discussing the struggle of modem day conservatives and liberals to define the
broad principles the farmers set forth in the constitution; recognizing).
102.
See e.g., Charles I. Lugosi, Conforming to the Rule of Law: When Person and
Human Being Finally Mean the Same Thing in Fourteenth Amendment Jurisprudence, 4
GEORGETOWN J. OF L. & POL'Y 361, 363-68 (2007) (discussing the right to life issue from a
legal perspective); James Rogers, Why it Matters That Some Rights Are "Inalienable", FOUND.
FOR ECON. EDUC. (Apr. 17, 2017), https://fee.org/articles/why-it-matters-that-some-rights-areinalienable/ (explaining the economic significance of inalienable rights).
103.
Leif Wenar, Rights, THE STANFORD ENCYCLOPEDIA OF PHIL. (Edward N. Zalta ed.,
Sept. 9, 2015), http://plato.stanford.edu/entries/rights/.
104.
See Craig A. Stern & Gregory M. Jones, The Coherence of Natural Inalienable
Rights, 76 UMKC L. REv. 939, 971-72 (2008).

105.
106.
107.

Id. at 958.
Id. at 953-54.
Is Healthcarea Right?, Student Voices, PBS NEWS
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that health care "should be a 'right' for every American."10 8 President
Donald Trump seems less sure, and has vacillated between two divergent
opinions.
During an interview in September 2015, Trump said,
"Everybody's got to be covered," remarking, "This is a very un-Republican
thing for me to say. '19 Later in Trump's presidential campaign, he framed
health care as a privilege, rather than a right, stating: "You have some guy
with no college degree working a minimum wage job; no ambition, no goals,
nothing to show for it. Yet for some reason, the current administration
believes he - and millions of people like him, should have access to health
insurance. It's outrageous." 0 Nonetheless, in March 2017, President Trump
lauded Australia's universal health care system.1 More recently, however,
President Trump seems against the notion that health care is a right that
11 2
should be available to all U.S. citizens.
The World Health Organization (WHO) Constitution preserves the highest
possible standard of health as a fundamental right of every human being. 1 3
However, the WHO's Constitution is not controlling law, and its guidance is
not dispositive. In National Federationof Independent Business v. Sebelius,

the United States Supreme Court came close to categorizing health care as a
"right" when it upheld an Individual Mandate under the Patient Protection
and Affordable Care Act (ACA). 1 4 However, the United States Supreme
Court has yet to conclusively label health care as a fundamental right.
The argument becomes more convoluted when determining what
constitutes "health care." It is untenable to equate an inalienable right to
health care with an inalienable right to receive a medical drug, even if that
http://www.pbs.org/newshour/extra/student-voices/debating-health-care-right-america/;
Mahiben Maruthappu et al., Is Health Care a Right? Health Reforms in the USA and their
Impact Upon the Concept of Care, 2(1) ANNALS OF MED. & SURGERY 15, 15 (2013),

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326121/pdf/main.pdf;

R. Hobbus, Donald

Trump: Healthcare is a Privilege, Not a Right, REAL NEWS RIGHT Now (Jan. 14, 2016),
http://realnewsrightnow.com/2016/01/donald-trump-healthcare-is-a-privilege-not-a-right/.
108.
Health care is a right: something's fundamentally wrong now, ON THE ISSUES
EVERY
POL.
LEADER
ON
EVERY
ISSUE
(2008),

http://www.ontheissues.org/socialbarack-obama-health-care.htm.
109.
Aaron Blake, Trump's Forbidden Love: Single-payer Health Care, WASH. POST
(May 5, 2017), https://www.washingtonpost.com/news/the-fix/wp/2017/05/05/trumps-

forbidden-love-singe-payer-health-care/?utm term=.a5a7a4477668.
110.
111.
repeal,

Donald Trump: Healthcare is a Privilege, Not a Right, supra note 107.
Ben Westcott, Trump praisesAustralia's universal health care after Obamacare

CNN
POLITICS
(May
5,
2017
3:53
AM),
http://www.cnn.com/2017/05/04/politics/trump-us-australia-health-care/index.html.
112.
Trump calls Sanders' single-payer plan 'a curse on the U.S. ', POLITICO (Sept. 14,
2017 03:51 PM), http://www.politico.com/story/2017/09/14/trump-bernie-sanders-single-

payer-health-plan-242728.
113.

Health

and

Human

Rights,

WORLD

HEALTH

ORG.

(Dec.

2015),

http://www.who.int/mediacentre/factsheets/fs323/en/.
114.
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drug is a cure. An argument for a patient's inalienable right to receive a cure
is specious because, in the modern health care model, the physician, rather
than the government, is responsible for determining options for treatment and
exercising prescribing power.)' 5 Therefore, a patient's "right to receive a
particular medical drug only extends as far as the government's facilitation
of a patient's access to that drug if, and only if, the patient's physician
determines the drug is appropriate for treating the patient. Restated, the
current physician-prescriber model preempts any inherent patient right to a
prescription drug.
It is worth noting the potential for patient collaboration; the physician and
patient may cooperate such that the physician can make the best decisions
about a patient's care and which medical drug to prescribe. 1 6 Nonetheless,
prescription of treatment for each patient is the sole responsibility of the
physician because the physician is the licensed expert. 1 Only the physician
is liable if the prescribed treatment harms the patient whereas it is the
patient's responsibility to comply with the prescribed treatment. 18
Physicians have a moral and ethical obligation to provide competent care
to patients.11 9 For chronic Hepatitis C patients, Sovaldi is now considered
the standard of care, whether in combination with RBV, RBV and pegINF,
or Ledipasvir.120 Nevertheless, a standard of care does not constitute a legal
obligation.
Whether a physician's denial of a curative drug, like Sovaldi, is ethical is
another question. Physicians are ethically obligated to do no harm.121 Most
physicians prescribe Sovaldi for their patients."'
Generally, evidence
123
indicates that most physicians act with the patient's best interest in mind.
A physician may consider Sovaldi inappropriate for an HCV patient for many
reasons; for example, a physician may opt not to prescribe Sovaldi based on

115.
Clayton Browne, Roles of Doctors & Nurses, CHRON, http://work.chron.com/rolesdoctors-nurses-10336.html (last visited Dec. 5, 2017).
116.
Id.
117.
Id.
118.
Id.
119.
AM. MED. Ass'N, AM. MED. Assoc. CODE OF MED. ETHICS: AM. MED. Assoc.
PRINCIPLES OF MEDICAL ETHICS (2001)

[hereinafter, AM.

MED.

Assoc.

CODE OF MED. ETHICS].

120.

Hepatitis C Fact Sheet, WORLD HEALTH ORG. (last updated Oct. 2017),
http://www.who.int/mediacentre/factsheets/fsl64/en/; Advances in Medications to Treat
Hepatitis C, AM. LrvER FOUND. (Oct. 2016), http://hepc.liverfoundation.org/treatment/thebasics-about-hepatitis-c-treatment/advances-in-medications/.
121.
See generally AM. MED. ASSOC. CODE OF MED. ETHICS, supra note 119.
122.
William Looney, Pharm Exec's 2015 Brand of the Year: Sovaldi and Harvonifor
Hepatitis C, PHARMEXEC.COM (May 12, 2015), http://www.pharmexec.com/pharm-execs2015-brand-year-sovaldi-and-harvoni-hepatitis-c?pagelD=1.
123.
David B. Resnik, The Patient'sDuty to Adhere to PrescribedTreatment: An Ethical
Analysis,
J.
OF
MED.
&
PHIL.
167,
176
(Aug.
16,
2006),

http://www.tandfonline.com/doi/full/10.1080/03605310590926849.
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potential contraindications. 2 In such cases, prescribing Sovaldi
would
25
potentially be detrimental to the patient's treatment regimen. 1
The argument that the denial of Sovaldi by physician determination is
tantamount to a "denial of access" to the drug is spurious. All patients have
access to Sovaldi. 126 The issue is not whether Sovaldi is accessible to all
HCV patients, but whether the barriers to certain patients' access are ethical
under principles of social justice.
Critically analyzing the Sovaldi controversy across the principles of
beneficence and social justice highlights certain aspects of the American
healthcare system, including: (1) increasing U.S. healthcare expenditure
trends and the price of other "curative" and "non-curative" drugs on the
market; (2) the role of health insurance companies in providing Sovaldi; and
(3) U.S. patent laws. Understanding nuances within the U.S. healthcare
system will make it easier to determine whether Gilead's economic and social
interests in developing new drugs are sufficiently balanced against the
economic and social interests of the HCV patients and insurance companies
that demand Sovaldi.
B.

Barriersto Receiving Sovaldi

Some patients experience prescriptive barriers to Sovaldi; however, for
patients to whom Sovaldi was prescribed, economic barriers abound. One
such economic barrier to Sovaldi treatment manifests in restrictions created
by health insurance companies. 127 The United States' health insurance
industry functions as a competitive market. 128 Since the late 1930s, with the
establishment of Blue Cross Blue Shield, private and public health insurance

124.
Sovaldi,
RxLIST,
http://www.rxlist.com/sovaldidrug.htm#overdosage-contraindications (last visited Nov. 14, 2017) [hereinafter, RxLIST];
U.S. FOOD & DRUG ADMIN., FDA DRUG SAFETY COMMUNICATION: FDA WARNS OF SERIOUS
SLOWING OF THE HEART RATE WHEN ANTIARRHYTHMIC

DRUG AMIODARONE IS USED WITH

HEPATITIS C TREATMENTS CONTAINING SOFOSBUVIR (HARVONI) OR SOVALDI IN COMBINATION
WITH
ANOTHER
DIRECT
ACTING
ANTIVIRAL
DRUG
(2015),

https://www.fda.gov/downloads/Drugs/DrugSafety/UCM439492.pdf.
125.
RxLIST, supra note 124.
126. Carolyn Y. Johnson & Brady Dennis, How an $84,000 drug got its price: 'Let's hold
our position.. .whatever the headlines,' THE WASH. POST (Dec. 1, 2015, 5:41 PM),
http://www.chicagotribune.com/business/ct-gilead-sciences-hepatitis-c-sovaldi-drug20151201-story.html (reporting that although the price for the drug was high, Gilead
executives say that it was "inline with previous standards of care").
127. Virgil Dickson, As insurerslimit access to hep C drugs,patients and doctors bristle,
MOD.
HEALTHCARE
(May
20,
2015),
http://www.modemhealthcare.conarticle/20150520/NEWS/150519897
(discussing
the
prior-authorization barriers put in place by an increasing number of insurers).
128. Kevin Dayaratha, Competitive Markets in Health Care: The Next Revolution, THE
HERITAGE
FOUND.
(Aug.
19,
2013),
http://www.heritage.org/health-carereformreport/competitive-markets-health-care-the-next-revolution.
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companies have been legally permitted to provide services to patients. 129
Prior to the ACA, the individual health insurance market was highly
concentrated with only modest competition in most states.130 The ACA
aimed to increase competition among private insurance companies across the
country. 131 However, there appears to be no nationwide consensus regarding
132
the ACA's true impact on the private insurance market.
The Social Security Administration recognizes Hepatitis C as a disability,
allowing HCV patients to qualify for Medicare. 133 However, the 2003
Medicare Modernization Act prohibits Medicare from negotiating discounts
with pharmaceutical companies,1 34 and prevents the government from
establishing a formulary. 135 However, these restrictions do not apply to
Medicaid, the Department of Veterans Affairs, and private health insurance
companies. 131
Generally, when health insurance companies decide not to distribute
Sovaldi to every patient with a prescription, the reasons can be ethical,
economic, or contractual in nature. 137 Many insurance companies cannot
afford to purchase large quantities of Sovaldi, and hence, only pay for a

129.

Michael A. Morrisey, History of Health Insurance in the United States, AM. COLL.
HEALTHCARE
EXECS.
3,
6-8
(2013),
https://www.ache.org/pubs/Morrisey2253-Chapter-1.pdf.
130.
Julie Brill, Competition in Health CareMarkets, HEALTH AFF. BLOG (Nov. 9, 2016),
http://healthaffairs.org/blog/2015/O1/26/competition-in-health-care-markets.
131.
Affordable
Care
Act
Facts,
OBAMACARE
FACTS,
https://obamacarefacts.com/affordable-care-act-facts/ (last visited Dec. 5, 2017).
132. See Reed Abelson & Haeyoun Park, ObamacareDidn't Destroy Insurance Markets,
but
It
Also
Didn't
Fix
Them,
N.Y.
TvnES
(June
6,
2017),
https://www.nytimes.com/interactive/2017/06/06/health/insurance-market-before-and-afteraca.html?mcubz=l&module=ArrowsNav&contentCollection=Health&action=keypress&regi
on=FixedLeft&pgtype=Multimedia (discussing the variance in impact of Obamacare on
states).
133.
Ram Meyyappan, Hepatitis C and Applying for Social Security Disability Benefits,
OF

DISABILITY BENEFITS CENTER

(Nov. 9, 2016), http://www.hepcassoc.org/pdf/social-security-

disability.pdf.
134.
Theodore T. Lee et al., The Politics of Medicare and Drug-Price Negotiation
(Updated),
HEALTH
AFF.
BLOG
(Sept.
19,
2016),
https://www.healthaffairs.org/action/showDoPubSecure?doi=10.1377%2Fhblog20160919.0
56632&format=full&
see
generally
What's
Medicare,
MEDICARE.GOV,
https://www.medicare.gov/sign-up-change-plans/decide-how-to-get-medicare/whatsmedicare/what-is-medicare.html (explaining the different categories of Medicare coverage).
135.
Ice Miller LLP, Survey of Recent Developments in Health Law, 39 IND. L. REv.
1051, 1058 (2006), https://mckinneylaw.iu.edu/ilr/pdf/vo140p931.pdf.
136.
Lee et al., supra note 134.
137.
See Sony Salzman, How insurance providers deny hepatitis C patients lifesaving
drugs,
ALjAZEERA
AMERICA
(Oct.
16,
2015,
5:00
AM),
http://america.aljazeera.com/articles/2015/10/16/insurance-providers-deny-hepatitisdrugs.html.
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limited number of HCV patients to receive treatment.13 8 When insurance
companies must ration Sovaldi due to the drug's high price, the rationale is,
first and foremost, economic. 139 However, in some cases, insurance
companies actively discriminate against certain types of patients regardless
of a drug's price.140 Deliberate discrimination may involve an ethical decision
to only pay for patients most likely to be compliant or who meet certain
criteria, or, it may involve a contractual obligation. 14 1For example, private
health insurance companies will often restrict which HCV patients can
receive Sovaldi when out of formulary. 142 Most private insurance companies
also require prior authorization. 143 Private insurance companies use some of
the following criteria to determine whether to pay for beneficiaries to
undergo a treatment regimen with Sovaldi: (1) the patient's genotype (most
health insurance companies will only pay for patients with genotype 1); (2)
the severity of the patient's illness; (3) the absence of significant or unstable
cardiac disease; (4) the absence of severe renal impairment requiring
138.
See, id. (explaining that the very high cost of Sovaldi, originally priced at roughly
$1,000 a pill, caused economic tension).
139.
Id.
140.
Olga Khazan, How Insurance Companies Still DiscriminateAgainst the Sick, THE
ATLANTIC
(Jan. 28, 2015), https://www.theatlantic.com/health/archive/2015/01/howinsurance-companies-still-discriminate-against-the-sick/384908/ ("No insurer wants to be
saddled with all the most-expensive customers, so they may all rejigger their drug co-pays to
be similarly harsh.").
141.
In medicine, patient compliance is a synonym for patient adherence and describes
the degree to which a patient correctly follows medical advice. Generally, a patient is
noncompliant if he/she does not take a prescribed medication or drug as ordered or
recommended by his/her physician, or, if the patient does not take care of himself/herself as
recommended by the physician or comply with other types of therapy sessions. Examples of
noncompliance include an HCV patient who skips days taking his/her medication or an HCV
patient who engages in risky activities, while undergoing his/her treatment regimen, that may
negatively impact the treatment outcome. Adherence to Long Term Therapies: Evidence for
Action,
WORLD
HEALTH
ORG.
(2003),
http://www.who.int/chp/knowledge/publications/adherence-full report.pdf (defining patient
adherence as "the extent to which the patient's history of therapeutic drug-taking coincides
with the prescribed treatment").
142.
See Shannon Firth, HCV Patients Face Obstacles to Treatment, MEDPAGE TODAY
(Aug. 2, 2016), http://www.medpagetoday.com/infectiousdisease/hepatitis/59485 (discussing
the use of formularies to restrict access to HCV medication); see also What is a Drug
Formulary,
ARISE
HEALTH
PLAN,
http://www.wecareforwisconsin.com/members/formulary/what is a drug-formulary
(last
visited Dec. 5, 2017) ("Aformulary for a health plan provides a list of medications that a team
of healthcare specialists have approved. A physician writes a prescription based on a patient's
medical needs, but the formulary provides him with recommendations from the pharmacist
and physician team. A formulary that is based on safety and cost considerations is useful for
limiting the drugs recommended by a patient's health insurance plan's healthcare
professionals.").
143.
See Dickinson, supra note 127 (Prior authorizations required by most insurance
companies before deciding whether they will pay for a patient's medicine limit use of
expensive treatments.).
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hemodialysis; (5) whether the patient is pregnant; (6) psychiatric illness; (7)
whether the patient has recently engaged in high risk behaviors such as drug
use, alcohol abuse, or prostitution; and (8) whether the patient has had a liver
transplant. 1" The many health insurance restrictions highlighted above,
therefore, limit patient access.
The question then arises whether it is ethical for health insurance
companies to set such restrictions. Usually, private insurance companies
prefer to pay for patients with genotype 1 to receive Sovaldi.145 Due to cost
constraints, patients with more severe liver dysfunction or cirrhosis resulting
from chronic Hepatitis C infection are more likely to be approved than
patients with milder symptoms, especially if the patient is potentially in need
of a liver transplant. 14 6 At first glance, it might seem unethical for insurance
companies to pick and choose which HCV patients they pay for; however, an
insurance company's decision to allocate Sovaldi to certain patients derives
from rational and economic considerations. 11
It is less costly for an
insurance company to pay for a twelve to twenty-four-week course of Sovaldi
treatment than to pay for a liver transplant; thus, it is more cost-effective to
treat patients with more advanced liver disease.148 Hence, while the principle
of utilitarianism ("maximizing the possible benefits") would ideally guide
insurance companies to maximize the number of HCV patients able to afford
Sovaldi through coverage, the high costs of the drug make such universal
drug coverage impossible.149 Therefore, insurance companies are not
ethically unjust for allocating coverage to patients with the most urgent
150
treatment needs.
The greatest limitation to widespread distribution of Sovaldi is the drug's
cost. 151 The price of Sovaldi is too high for many insurance companies to

144.
Prior AuthorizationNotification Sovaldi, UNITED HEALTHCARE
(2014),
https ://www.uhcprovider.com/
content/dam/provider/docs/public/priorauth/drugspharmacy/Notification_ Sovaldi.pdf.
145.
Michelle Andrews, Hepatitis C patients may not qualify for pricey drugs unless
illness
is
advanced,
THE
WASH.
POST
(Nov.
4,
2014),
https ://www.washingtonpost.com/national/health-science/hepatitis-c-patients-may-notqualify-for-pricey-drugs-unless-illness-is-advanced/2014/11/03/6d0646bc-5f71-11e4-9f3a7e28799e0549_story.html?utm term-.4882b89caad7; Felice J. Freyer, Hepatitis C patients
often have to get sicker before insurance will pay for drugs, Bos. GLOBE (Apr. 19, 2016),
https://www.bostonglobe.com/metro/2016/04/18/insurers-balk-paying-for-hepatitisdrugs/M9JvOSZcMhHuwlek3zclLL/story.html.
146.
Andrews, supra note 145; Freyer, supra note 145.
147.
Andrews, supra note 145.
148.
Michael Smith, Treating HCV Is the Price Right?, MEDPAGE TODAY (Feb. 18,
2014), https://www.medpagetoday.com/gastroenterology/hepatitis/44357.
149.
Sovaldi: Who's to Blame, supra note 24.
150.
Id.
151.
See Bertha Coombs, Sovaldi $55 Billion Headache for States, CNBC (July 17,
2014, 10:18 AM), http://www.cnbc.com/id/101842469 (showing a state-by-state comparison
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handle without going bankrupt.15 2 For example, if all HCV patients eligible
for Medicaid coverage were treated in 2015, the cost to the states would be
$55 billion. 3 Similar costs would engulf the prison system. 15 4 For example,
although less than one percent of over 106,200 state prisoners with HCV
were recently treated with Sovaldi combination therapies, due to the drug's
high cost, at least $39.8 million was spent annually on HCV therapies. 155 If
the remaining ninety-nine percent of HCV infected inmates received Sovaldi
156
treatment, the financial burden on tax payers would be enormously high.
As a result, most states place several restrictions on access. 157 Ethically, this
dilemma is challenging for insurance companies and policy makers because
Sovaldi was proven to work best in patients who do not have advanced liver
disease, and to some, it may seem unjust to wait until someone is extremely
sick before paying for treatment. 158 However, because of limited resources
and high drug costs, insurance companies are not ethically unjust for
allocating coverage to patients with the most urgent treatment needs. After
all, if it is only possible for an insurance company to provide Sovaldi to a
limited number of HCV patients, it is reasonable that the HCV patients
chosen to receive Sovaldi are those who are at highest risk of mortality and
severe complications costly to the healthcare system.
Furthermore, prior authorizations - insurance companies' primary means
of restricting drug coverage - are ethically justifiable. 159 Prior authorizations

of state spending on hepatitis C medications).
152.
John Rother, Sovaldi: Chartingand UnsustainablePath, MORNING CONSULT (July
23, 2014), https://morningconsult.com/opinions/sovaldi-charting-unsustainable-path/.
153.
Coombs, supra note 151.
154.
Ed Silverman, Less than 1 percent of state prisonerswith hepatitis C get treateddue
to drug costs, STAT (Oct. 5, 2016), [hereinafter, Less than 1 percent of state prisoners with
hepatitis C] https://www.statnews.com/pharmalot/2016/10/05/prisons-hepatitis-drug-prices-

gilead/.
155.

Id.

156.
Id.; see Study: Modern Hepatitis C Drugs are Very Costly and Unavailable to Many
State Prisoners, YALE L. SCH. (Oct. 4, 2016), https://law.yale.edu/yls-today/news/study-

modern-hepatitis-c-drugs-are-very-costly-and-unavailable-many-state-prisoners.
157.
See Soumitri Barua et al., Restrictionsfor Medicaid Reimbursement of Sofosbuvir
for the
Treatment of Hepatitis C Virus Infection in the UnitedStates, ANNALS OF INTERNAL MED. 215,
215
(2015),
http://annals.org/aim/article/2362306/restrictions-medicaid-reimbursement-

sofosbuvir-treatment-hepatitis-c-virus-infection-united ("Twothirds of states have restrictions
based on prescriber type, and 88% include drug or alcohol use in their sofosbuvir eligibility
criteria, with 50% requiring a period of abstinence and 64% requiring urine drug screening.").
158.
Hepatitis C Treatment Factsheet: Sofosbuvir (Sovaldi), INFOHEP (Oct. 2016),
http://www.infohep.org/v636132534599770000/file/1187172/sofosbuvir hep-c-factsheet.pd

f ("Sofosbuvir can be used by people with all stages of liver disease including compensated
and decompensated cirrhosis. However, it works better for people with less advanced liver
damage.").
159.
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can be deemed reasonable, fair, and economically just because they take into
consideration a patient's well-being and allocate the drug to patients who are
more likely to be compliant, experience a better treatment outcome, and

optimally utilize the drug.160 Certain patient populations are more vulnerable
to negative effects from Sovaldi. 16 1 For instance, Sovaldi may worsen the
health of patients with cardiac disease or psychiatric illness. 162 Patients on
hemodialysis and patients who engage in drug use are at high risk for
continual exposure to varying strains of HCV. 163 Patients who abuse alcohol
are more likely to worsen their liver conditions and respond poorly to
treatment. 164 Prior authorizations allow insurance companies to screen such
vulnerable patients from Sovaldi coverage, thereby protecting the
individual's well-being, and also allowing insurance companies to minimize
future costs so that they afford to purchase Sovaldi and provide it to other
165

patients.
To conclude, universal access to Sovaldi is conditioned on physicians'
prescribing power and, in light of the drug's astronomical cost, payers' need
to allocate coverage. 166 Certainly, the more dominant the private insurer, the
better that insurer is at negotiating drug prices with pharmaceutical
companies like Gilead. 167 Deciding how a curative medical drug should be
rationed to three million patients with an infectious disease is no small task

should not be focused on insurance companies, rather "the patent system as a whole"); see
also Ed Silverman, Interview with Illinois Medicaid Medical Director Re: their new
restrictionson Sovaldi Access, NATAP (Aug. 3, 2014, 9:15 PM), [hereinafter, Interview with
Illinois Medicaid Medical Director] http://www.natap.org/2014/HCV/080814 _07.htm

(discussing why insurance companies rationing methods in favor of more advanced stage
hepatitis C is not unjustifiable, the reality of high cost must be considered).
160.

See generally, Interview with IllinoisMedicaidMedical Director,supra note 159.

161.
Id.
162.
Gilead Sciences, Inc., Sovaldi, FDA ProfessionalDrug Information, DRUGS.COM
(last updated Apr. 2017), https://www.drugs.com/pro/sovaldi.html.
163.
WA Alashek & M Altagdi, Risk Factors and Genotypes of Hepatitis C Virus
Infection in
Libyan Patients, 3(4) LIBYAN
J. MED.
162,
162 (2008),

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC 3074306/pdf/LJM-3-162.pdf.
164. Eugene R. Schiff & Nuri Ozden, HepatitisC andAlcohol, NAT'L INSTS. OF HEALTH:
NAT'L
INST.
ON
ALCOHOL
ABUSE
& ALCOHOLISM
(Sept.
29,
2004),
https://pubs.niaaa.nih.gov/publications/arh27-3/232-239.htm.
165.

154.
166.

See generally, Less than 1 percent of state prisoners with hepatitis C, supra note

Barua et al., supra note 157, at 220-21.

167.
Michael Hiltzik, Allowing Medicare to negotiate drug prices is a popular solution
to healthcare costs. But it may not work, L.A. TgIES (Jan. 11, 2017, 3:40 PM),

http://www.latimes.com/business/hiltzik/la-fi-hiltzik-medicaire-negotiate-201701 11story.html; Paul Barrett & Robert Langreth, The Crazy Math Behind Drug Prices,BLOOMBERG
BUSINESSWEEK (June 29, 2017, 11:00 AM), https://www.bloomberg.com/news/articles/201706-29/the-crazy-math-behind-drug-prices.
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for a health insurance company.168 In order for insurance companies to
increase their supply of Sovaldi, and consequently distribute Sovaldi to more
patients, the price must drop.169 The issue then becomes whether Gilead acted
unethically in setting Sovaldi's price so high that policy makers and
insurance companies must determine how best to ration the drug.

V.

THE ETHICAL DEBATE INVOLVING GILEAD

Many Americans have accused Gilead of price gouging."' Price gouging
occurs when a company charges a price that is higher than what is considered
normal or fair.1"1 The practice is best framed as "increases in price due to
temporary increase in demand, rather than increases in suppliers' costs." ' 2
In other words, when there is a sharp increase in the demand of a good
relative to its supply, there will be a shortage of the good unless the
manufacturer raises the price in order to decrease demand, giving the
manufacturer time to increase supply."3 On its face, price gouging is
unethical because it undermines the principle of social justice by creating an
economic scheme close to a monopoly, and a monopoly leads to a disparity
of allocated resources because only people who are most willing and able to
purchase the good do so. 1 74 However, there is no conclusive evidence that
Gilead was guilty of unethical price gouging. 1 71 Certainly, that a drug

168.
See generally, Lawsuit Alleges Price Gouging, supra note 22.
169.
Id.
170.
Id. (citing experts, including Professor C. Scott Hemphill, a Columbia Law School
professor, who viewed SEPTA's antitrust claim as meritless because "having a monopoly and
setting high prices do not violate antitrust law."); Breakthrough Hepatitis C Drug Causes
Controversy,
ADVANCED
RES.
INST.
(last
visited
Dec.
5,
2017),
http://www.advresearch.org/breakthrough-hepatitis-c-drug-causes-controversy/
(citing
legislators and insurance companies, among others, of accusing Gilead of unethical practices
due to their pricing scheme).
171. Jodi Beggs, What is Price Gouging?, THOUGHTCO. (Apr. 1, 2017),
http://economics.about.com/od/changes-in-equilibrium/ss/The-Economics-Of-PriceGouging.htm.
172. Id.
173. Id.
174.
Price Gouging, LEGAL DICTIONARY, https://legaldictionary.net/price-gouging/. (last
visited Dec. 5, 2017) (defining "price gouging").
175.
Brady Huggett, America's Drug Problem, 34 NATURE BIOTECHNOLOGY 1231, 1233
(2016), http://www.nature.com/nbt/joumal/v34/n12/full/nbt.3734.html;
Andrew Pollack,
Gilead Faces Fights Over Hepatitis C and H.I.V. Drugs, N. Y. TIMES (Jan. 27, 2016),
https://www.nytimes.com/2016/01/28/ business/gilead-faces-fights-over-hepatitis-c-and-hivdrugs.html ("Gilead has argued that the prices are justified by the value provided by the drugs,
curing a disease that gradually destroys the liver."); Lawsuit Alleges Price Gouging, supra
note 22 ("Gilead 's pricing is unlikely to be considered illegal, experts say. The transit agency
is 'complaining about high prices. But having a monopoly and setting high prices do not
violate antitrust law,' says C. Scott Hemphill, a Columbia Law School professor who
specializes in antitrust issues and intellectual property. 'Judging from the complaint, the
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becomes less expensive after coming off-patent does not definitively indicate
any existence of price gouging on-patent.1 6 Sans evidence that Gilead would
refuse to drop Sovaldi's price to adjust to the changing market value if other
drug manufacturers dropped the prices of competing Hepatitis C drugs, there
is insufficient evidence to prove that Gilead behaved unethically or, for that
matter, acted unlawfully.1 77 Furthermore, there is no evidence that Gilead's
decision to adjust its price was not a response to a shifting market; the fact
that Gilead already recouped so much money suggests that American
consumers and health insurance companies are actually willing and able to
purchase the product at $1,000 per pill.1 8 The following sections shed light
on some of the reasons Gilead's actions appear to be ethically reasonable.
A.

Sovaldi 's SuperiorQuality Justifies its Price

Probably the most obvious justification for Sovaldi's high price is the
superior quality compared to other Hepatitis C drugs currently on the
market.1 7' Gilead issued a public statement,
"We believe the price of Sovaldi reflects the value of the medicine.
Sovaldi represents a significant therapeutic advance over other available
therapies, as it has shortened the duration of treatment to as little as 12 weeks
and has reduced or completely eliminated the need for interferon injections,
depending on the patient's genotype." '
Gilead further contended that the price of Sovaldi (in conjunction with
interferon and ribavirin) was consistent with that of competing protease

antitrust claim is meritless."').
176. See, Lawsuit Alleges Price Gouging, supra note 22 (quoting Ankur Kapoor,
"Monopolists, themselves, are not unlawful. They are allowed to charge any price they want.
It's only if they take any anticompetitive conduct that a problem may exist").
177. Huggett, supra note 175, at 1233-35 (suggesting that the price of Sovaldi has
adjusted for changing market value); Sovaldi: Who's to Blame, supra note 24 (citing Professor
Patricia Danzon, Wharton professor of health care management, "Generally we do not adjust
prices in a market- based system based on the number of consumers. Price is more related to
value.").
178. Huggett, supra note 175, at 1233-35; Sovaldi: Who's to Blame, supra, supra note 24
(stating that Sovaldi was predicted to hit $1-2 billion in its first quarter of sales and surpass
Lipitor as the top-selling drug of all time); Max Nisen, The staggering success of Gilead's
hepatitis drugs, in one chart, QUARTZ (July 28, 2015), https://qz.com/466269/thestaggering-success-of-gileads-hepatitis-drugs-in-one-chart/.
179.
Pollack, supra note 175 ("Gilead has argued that the prices are justified by the value
provided by the drugs, curing a disease that gradually destroys the liver."); Anne Harding,
Pros
and
Cons
of
New
Hepatitis
C
Drugs,
EVERYDAY
HEALTH,
https://www.everydayhealth.com/news/pros-cons-new-hepatitis-treatments-patients/
(last
updated Apr. 7, 2015) (describing the Sovaldi and Harvoni, a combination of Sovaldi and
ledipasvir, as having superior treatment outcomes than other Hepatitis C drugs).
180.
Sovaldi: Who's to Blame, supranote 24.
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inhibitors for treating Hepatitis C on the market. 81 Moreover, Gilead shared
that Sovaldi was projected to save money for the healthcare system over time
by significantly reducing long-term complications of the disease, such as the
need for liver transplants and liver failure, whereas competing HCV drugs
will not. 8 2 These projected savings appear plausible. The average cost of a
liver transplant, including necessary pre-operative and post-operative
expenses, is $577,100.83 The cost of being admitted to the hospital for liver
failure is estimated to be $110,576 and that number does not include hospital
stay. 8 4 After adding those costs, more than $687,676 will be spent on each
patient admitted to the hospital with end stage liver disease (ESLD) who
receives a liver transplant. This cost for an individual is equivalent to the cost
necessary to treat more than eight HCV patients with Sovaldi for a 12-week
cycle. 8 5 Considering that the healthcare system 8 6 paying for the brunt of
liver transplants and ESLD-related hospital visits is the same healthcare
system spending $84,000 to cure one patient who will likely never need a
costly treatment again after completing a twelve to twenty-four-week
18 7
treatment regimen on Sovaldi, Gilead seems to make a valid point.
Sovaldi's superiority to other competing HCV drugs further buttresses its
higher price. 88 First, Sovaldi carries a lower frequency of the harsh side

181. Id.
182. Id.
183. Financial
Matters:
Liver
Transplant
Costs,
SUTTER
HEALTH
http://www.cpmc.org/advanced/liver /patients/topics/finance.html#Transplantation%20Costs
(last visited Dec. 5, 2017).
184. Linda L. Wong et al., The Cost of Dying of End-stage Liver Disease, 157 ARCHIVES
OF INTERNAL MED.

1429, 1432 (1997).

185. Sofosbuvir
(Sovaldi),
HEPATITIS
C
ONLINE,
https://www.hepatitisc.uw.edu/page/treatment/drugs /sofosbuvir-drug (last visited Dec. 5,
2017).
186.
STRENGTHENING HEALTH SYSTEMS TO IMPROVE HEALTH OUTCOMES, WORLD
ORG.
1,
2
(2007),
http://www.who.int/healthsystems/strategy/
everybodys business.pdf (According to the World Health Organization, a healthcare system
consists of "all organizations, people and actions whose primary intent is to promote, restore
or maintain health. This includes efforts to influence determinants of health as well as more
direct health-improving activities. A health system is therefore more than the pyramid of
publicly owned facilities that deliver personal health services. It includes, for example, a
mother caring for a sick child at home; private providers; behavior change programs; vectorHEALTH

control campaigns; health insurance organizations; occupational health and safety legislation.

It includes inter-sectoral action by health staff, for example, encouraging the ministry of
education to promote female education, a well-known determinant of better health.").
187.
Carolyn Johnson, How an $84,000 Drug Got Its Price: 'Let's Hold Our
Position... Whatever
the
Headlines, '
THE
WASH.
POST
(Dec.
1,
2015),
https://www.washingtonpost.com/news/wonk/wp/2015/12/01/
how-an-84000-drug-got-its-

price-lets-hold-our-position-whatever-theheadlines/?utm

term=.7280e996bbfe.

188.
Michael Hiltzik, Is That $100,000 Hepatitis Treatment Worth the Price? Yes, but
Can
Society
Afford
It?,
L.A.
TIMES
(Jan.
15,
2016),
http://www.latimes.com/business/hiltzik/la-fi-mh-that-hepatitis-treatment-201601 11-
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effects of the previously standard therapies, RBV and pegIFR.189 The
combination therapy of RBV and pegIFR carried the potential to cause severe
hemolytic anemia and other harsh side effects.190 Second, Sovaldi's cost,
$1,000 per pill,191 is comparable to the cost of other HCV drugs on the market
and renders future health economic outcomes that are more favorable than
other treatment regimens.192 Finally, Sovaldi surpasses the former therapies
in effectiveness; the drug was over ninety percent curative in patients
enrolled in Gilead's Phase III clinical trials after 12-weeks of treatment, while
the combination of RBV and pegIFR only sustained a virological response
193
(SVR) rate of thirty-five to sixty-six percent.
Some of Sovaldi's competitors include Telaprevir, Boceprevir, and
Simeprevir; however, these drugs are far less efficacious and far more
burdensome to patients living with chronic Hepatitis C, and out of these four
HCV drugs, only1 94 Sovaldi is regarded clinically as a "cure". 195 Telaprevir,
manufactured by Vertical Pharmaceuticals, costs $49,200 for a 12-week
course of therapy, but has a high pill burden, which provides an opportunity

column.html.
189.
Harvoni and Depression: What's the
Connection?, HEALTHLINE,
https://www.healthline.com/health/ hepatitis-c/harvoni-depression#overviewl (last visited
Dec. 5, 2017) (When not combined with RBV or pegIFR, drugs containing Sovaldi, such as
Harvoni, carry a low frequency of side effects.); see also Harvoni vs. Sovaldi: A Side-by-Side
Comparison,
HEALTHLINE,
https://www.healthline.com/health/hepatitis-c/harvoni-vssovaldi#side-effects4 (last visited Dec. 5, 2017).
190.
HCV Medications: Ribavirin, supra note 44 (listing influenza-like symptoms,
nausea, myalgia, neutropenia, thrombocytopenia, insomnia, and depression as additional side
effects to the ones already mentioned).
191.
Sam Aminov, Epclusa Approved for Chronic Hepatitis C, MYMATRIXX (July 8,
2016), https://www.mymatrixx.com/new-drug-alert-epclusa-approved-for-chronic-hepatitis-

cI.
192.
S. Saab et al., Cost-Effectiveness Analysis of Sofosbuvirplus peginterferon/ribavirin
in the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection, 40 ALIMENT.
PHARMACOL. THER. 657, 669 (2014).
193.
Graham R. Foster, Pegylated Interferonsfor the Treatment of Chronic Hepatitis C:
Pharmacological and Clinical Differences Between Peginterferon-alpha-2a and
Peginterferon-alpha-2b,70 DRUGS 147, 147 (2010).
194.
Zepatier vs Harvoni vs Epclusa: Which One is the Best for You?, HEPATITIS C
SOCIETY (last updated, June 28, 2016), http://104.236.45.254/hepc-drugs-comparisonharvoni-vs-sovaldi-vs-viekirapak-vs-zepatier/
(Since Sovaldi, and other combination
therapies that include Sovaldi (such as Harvoni and Epclusa), hit the market, a couple more
HCV "cures" have been FDA approved for treating genotype 1, including Viekira Pak,
Daklinza, and Zepatier. Deciding which of these HCV drugs is the most optimal treatment is
patient dependent. Viekira Pak and Daklinza are priced about the same as Sovaldi. Zepatier,
the newest addition to the market (added in 2016) is priced at a lesser price of $54,600 per
treatment regimen. However, Zepatier has more adverse side effects than Sovaldi.).
195.
See supra note 7; FairPricing Coalition Expresses Disappointment at the Price of
Vertex's Newly Approved Hepatitis C Drug, FAIR PRICING COALITION (May 24, 2011),
https://fairpricingcoalition.org/2011/05/24/the-fair-pricing-coalition-expressesdisappointment-at-the-price-of-vertexs-newly-approved-hepatitis-c-drug.
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for a patient to be noncompliant. 96 Furthermore, Telaprevir can potentially
cause adverse events such as anorectal complaints, rash, anemia, and even
serious conditions such as Steven's Johnson Syndrome.19 Additionally, for
every adverse side effect, patients will need additional costly medical care.198
Adding to the limitations of Telaprevir is the fact that the drug has a rapid
resistance to HCV in genotype 1 patients, significantly reducing its efficacy
and potential to keep patients in remission.199
Similarly, Boceprevir can cost close to $50,000 for one course of treatment
in patients with cirrhosis, but it is known for serious side effects and
extremely high HCV resistance.20 0 Its high resistance to HCV causes greater
than fifty percent of patients to never achieve an acceptable SVR rate.2 1
Boceprevir has an even higher pill burden than Telaprevir, with patients
taking up to 12 pills per day, plus a weekly injection of PEG-IFN.20 2
Simeprevir costs $66,360 for a 12-week supply, has an extremely high
resistance to HCV, and causes side effects such as rash, nausea, and serious
photosensitivity reaction.2 3
Furthermore, Telaprevir, Boceprevir, and
Simeprevir are typically only effective in one of the six genotypes and are no
longer the standard of care for treating patients with genotype 1.2"
Sovaldi, by contrast, can successfully treat patients with HCV genotypes
1-4 and has a high barrier to resistance that makes it practically curative,
while also being able to achieve a high SVR rate in over ninety percent of
patients. 205 Drugs that contain Sovaldi, such as Epclusa and Harvoni, have a

196.

Id.

197.
A. Sidney Barritt, IV & Michael W. Fried, Maximizing Opportunities & Avoiding
Mistakes in Triple Therapy for Hepatitis C Virus, 142 GASTROENTEROLOGY 1314, 1320
(2012).

198.
199.

Id.
Id. at 1316.

200.
Jagpreet Chhatwal et al., Cost-effectiveness of Boceprevir in Patients Previously
Treated for Chronic Hepatitis C Genotype 1 Infection in the U.S., 16 VALUE HEALTH 1, 7

(2013).
201.

Boceprevir
(Victrelis),
HEPATITIS
C
ONLINE,
https://www.hepatitisc.uw.edu/page/treatment/ drugs/boceprevir-drug/drug-summary
(last
visited Dec. 5, 2017).
202.
Barritt & Fried, supra note 197, at 1316 ("..boceprevir is prepared as 200-mg
capsules and dosed as 4 capsules (800 mg), 3 times a day, 7-9 hours apart, with food.").
203.
Simeprevir (Olysio), HEPATITIS C ONLINE, (Stating that patients on Simeprevir are
urged to stay out of the sun) http://www.hepatitisc.uw.edu/page/treatment/drugs/simeprevirdrug (last visited Dec. 5, 2017).
204.
David H. Spach & H. Nina Kim, Treatment of HCV Genotype 1, HEPATITIS C
ONLINE
(last visited Dec. 5,
2017) https://www.hepatitisc.uw.edu/go/treatmentinfection/treatment-genotype- 1/core-concept/all.
205. Paul Kwo, The Future of Hepatitis C Virus Therapeutics, 10 GASTROENTEROLOGY
HEPATOLOGY 433, 435 (2014); see also Sovaldi Highlights of PrescribingInformation,FOOD
&

DRUG

ADMIN.

https://www.accessdata.fda.gov/drugsatfda-docs/label/2015/204671sOO41bl.pdf
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far superior efficacy to all of the other HCV drugs on the market. 20 6 These
drugs can also be used without PEG-IFN,20 and are even effective in treating
patients with liver disease. 20 8 Additionally, patients taking Sovaldi only have
to take one tablet per day and the only known side effects are fatigue and
mild headaches - two mild conditions that rarely require additional medical
expense.20 9 Not only do harsh side effects harm patients in violation of the
"do no harm" principle, harsh side effects often cause patients to stop
complying with treatment altogether, and many patients on competing
protease inhibitors with low HCV resistance will end up requiring treatment
again in the future. 0 Therefore, even though Sovaldi costs more upfront than
competing protease inhibitors, its efficacy makes it, comparatively, more
cost-effective. 2 11 Additionally, it cannot be minimized that Sovaldi
dramatically improves the patient's quality of life in curing HCV.212
Most developed countries, including the United Kingdom, 213 have a
mechanism for setting limits on what drugs should cost.214 This mechanism
is based on a party's willingness to pay a certain amount for a "quality

Dec. 5, 2017).
206. Gilead's All-Genotype Hep C Drug Boasts Excellent Cure Rates, HEPMAG (Sept.
23, 2015),
https://www.hepmag.com/article/Gilead-8217-s-All-Genotype-Hep-C-DrugBoasts-Excellent-Cure-Rates-27833-1885851337; see also Epclusa: The Newest Hepatitis C
Treatment, HEPMAG (June 28, 2016), https://www.hepmag.com/blog/epclusa-newesthepatitis-c-treatment.
207.
Epclusa: The Newest Hepatitis C Treatment, supra note 206 (There are many
patients who are ineligible to receive peg-IFN. Sovaldi gives them an alternative treatment
option.); see also Chronic Hepatitis C Virus (HCV) Infection, supra note 39; see also Alan
Hoi Lun Yau & Eric M. Yoshida, HepatitisC Drugs:The End of the PegylatedInterferon Era
and the Emergence of an All-Oral, Interferon-FreeAntiviralRegimens: A Concise Review, 28
CAN.

J.

GASTROENTEROL. HEPATOL.

445, 447 (2014).

208.
Joel V. Chua & Shyam Kottilil, Sofosbuvir and Velapatasvir:A Stellar Option For
Patientswith Decompensated Hepatitis C Virus (HCV) Cirrhosis,4 ANN. TRANSL. MED. 1, 4
(2016).
209.
Chronic Hepatitis C Virus (HCV) Infection, supra note 39, at 19.
210.
Sobia Kanwal & Tariq Mahmood, Hepatitis C Virus Resistance to Interferon
Therapy: An Alarming Situation, 9 CENT. EUR. J. BIOL. 1155, 1167 (2014).
211.
Sovaldi Cost-Effectiveness/Disease Outcome Analysis, NAT'L AIDS TREATMENT
ADVICE CTR., http://www.natap.org/2014/HCV/101014_02.htm (last visited Dec. 5, 2017);
Perica Davitkov et al., Treatment Selection Choices Should Not Be Based on Benefits or Costs
Alone: A Head-to HeadRandomized Control Trialof Antiviral Drugsfor HepatitisC, 11 PLOS
ONE
1,
11
(2016);
see
also
Boceprevir:
Overview,
LIVERTOX,
https://livertox.nih.gov/Boceprevir.htm (last visited Dec. 5, 2017).
212. Denise Grady, Are New Drugs for Hepatitis C Safe? A Report Raises Concerns,
N.Y. TIMES (Jan. 24, 2017).
213. Peter J. Neumann et al., Updating Cost-Effectiveness: The CuriousResilience of the
$50,000-per-QALY Threshold, NEW ENGLAND J. OF MED. (Aug. 28, 2014),
http://www.nejm.org/doi/full/10.1056/NEJMp1405158?af=R&rss=currentlssue#t=article
(While many U.S. policy makers utilize QALY measurements when making policy decisions,
the U.S. has legislated against the explicit use of cost-per-QALY thresholds.).
214. Sovaldi: Who's to Blame, supranote 24, at 3.

https://lawecommons.luc.edu/annals/vol27/iss1/3

26

Mahfood: Sovaldi: The High Price for a Cure

2018

Sovaldi

adjusted life year" (QALY) saved.]' A QALY measures disease burden,
including the quality and quantity of life lived, and is often used in assessing
what monetary value should be placed on a medical intervention. 16 Research
suggests that on average, the more expensive HCV drug combinations, such
as Sovaldi, Olysio, and RBV (without PEG-IFN), yield a higher QALY value
than less expensive drug combinations and save significantly more money in
the long run.21 Hence, based on these QALY measurements, Gilead
reasonably believes that Sovaldi is a far superior product to competing HCV
drugs on the market.2 18 The question then becomes whether it is ethical for
pharmaceutical companies to use the high quality of a drug as justification
for setting high prices, which causes many patients to experience greater
financial barriers. There is no simple answer. However, one may reasonably
argue that this practice is ethical because it will likely benefit far more
patients in the long run by increasing incentives and resources for continued
R&D, leading to the discovery of newer, better medications. Currently,
Gilead's patent stands to expire in about ten years, at which point the price
of Sovaldi will drop significantly in the U.S. 2 9 The next section of this paper

expounds upon these concepts in more detail.
B.

Sovaldi's Price Reflects Legal ConstructsInfluencing the US.
HealthcareSystem

Many opponents of Gilead are quick to call the company unethical for
Sovaldi's high price.220 However, several factors, partly out of Gilead's
control, contribute to Sovaldi's high price. 2 Many scholars agree that the
healthcare reimbursement and patent systems, in addition to the frequentlyvilified pharmaceutical companies, should bear responsibility for high drug

215.
216.
HEALTH

Id.
Measuring Effectiveness and Cost Effectiveness: The QALY, NAT'L INST. FOR
&

CLIN.

EXCELLENCE,

https://web.archive.org/web/20090809 124835/http://www.nice.org.uk/newsroom/features/m
easuringeffectivenessandcosteffectivenesstheqaly.jsp (last visited Dec. 5, 2017).
217.
Sovaldi-Olysio-Ribavirin Cost-Effective Over Sovaldi-Ribavirin, HEPMAG,
http://www.hepmag.com/articles/Sovaldi cost 2501_25467.shtml (last visited Dec. 5, 2017).
218.
Yevgeniy Feyman, UK Says Sovaldi Is Worth It.We Should Listen., FORBES (Oct.
18, 2014), https://www.forbes.com/sites/theapothecary/2014/08/18/uk-says-sovaldi-is-worthit-we-should-listen/#4229e72d7569.
219.
Id.
220.
Breakthrough Hepatitis C Drug Causes Controversy, ADVANCED RES. INST.
http://www.advresearch.org/breakthrough-hepatitis-c-drug-causes-controversy/ (last visited
Dec. 5, 2017) (citing legislators and insurance companies, among others, of accusing Gilead
of unethical practices due to their pricing scheme).
221.
Hagop M. Kantarjian, et al., Cancer Drugs in the United States: Justum Pretium
The Just Price, 31 J. OF CLIN. ONCOLOGY 3600, 3602 (2013).
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prices.222 While politicians now bemoan Gilead's prices, asking the company
to release years of data regarding its expenditures, it bears remembering that
politicians have, to date, established no limits to the amounts pharmaceutical
companies can charge.223 Ultimately, the U.S. patent system, when combined
with increased healthcare expenditures, drives novel drug prices so high.224
In fact, prices of new drugs have doubled in the past decade,225 and Sovaldi
is far from being the most expensive drug on the market.226 In 2012 alone,
the FDA approved twelve different cancer drugs, eleven of which cost more
than $100,000 per year.22 7 In 1989, a powerful, newly discovered HIV drug,
AZT, was priced at just $8,000 per year.228

Today, even inefficacious

antivirals are priced at more than $30,000 per year.22 9 This trend of rising
drug prices is more closely tied to healthcare costs and reimbursement than
the ethics of drug manufacturers. 30
Generally, most pharmaceutical companies, including Gilead, function
with two very important, although conflicting, goals in mind: (1) to
encourage a competitive market that typically includes generic competitors;
and (2) to benefit as many patients as possible. 21 The first goal safeguards
that affordable drugs are widely available to as many patients as possible,
ensuring economic justice.232 In order to meet this goal, pharmaceutical
prices must reflect the marginal costs of production, which unfortunately
means relatively high drug prices. 233 Restated, pharmaceutical companies

222.
Id.; Who's to Blame for the $1,000 a Day Cure? KNOWLEDGE @ WHARTON (Apr.
16, 2014) http://knowledge.wharton.upenn.edu/article/sovaldi-whos-blame-1000-day-cure/
(quoting Professor Patricia Danzon at the Wharton School of University of Pennsylvania as
saying, "Companies obviously have an obligation to their shareholders to maximize profits ...
that generally means doing the best that you can within the reimbursement environment that
exists in any particular country. In the U.S., we have established a system of reimbursement
for pharmaceuticals that unfortunately puts absolutely no limits on the prices that companies

can charge.").
223.
John R. Graham, PoliticizingGilead'sResearch and Development Costsfor Sovaldi
Is
a Reckless
and Dangerous Misadventure, FORBES
(July
25,
2014),
https://www.forbes.com/sites/theapothecary
/2014/07/25/politicizing-gileads-research-anddevelopment-costs-for-sovaldi-is-a-reckless-and-dangerous-misadventure/#3f62b0418650.
224.
See Wong et al., supra note 184.
225.
See Kantarjian, et al., supra note 221, at 3600.
226.
Id.
227.
Id.
228.
AZT's
Inhuman
Cost,
N.Y.
TMWES
(Aug.
28,
1989),
http://www.nytimes.com/1989/08/28/opinion/azt-s-inhuman-cost.html.
229.
Kantarjian, et al., supra note 221, at 3600.
230.
See generally, id.
231.
Wayne Winegarden, The Economics of PharmaceuticalPricing, PAC. RES. INST. 1,
5 (2014).
232.
Id.
233.
Id.; Sean Ross, How Does Marginal Cost of Production Relate to Economies of
Scale?,
INVESTOPEDIA
(Jan.
30,
2015),
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must adequately recoup capital costs in order to continue providing additional
future drugs to patients.2 34 The second goal fulfills a pharmaceutical
company's ethical obligation, under the principle of beneficence, to place
high value on the welfare of each human subject so that generalized
knowledge can have future long run benefits for all patients living with the
disease in question.23 5
The current U.S. patent system provides a way for innovative
pharmaceutical companies to prevent short-run competition against generics
so that they can have a greater opportunity to recoup their costs. 236 Any
pharmaceutical company, including Gilead, is permitted to set prices of
newly developed drugs at high rates, so long as the company does not violate
pricing discrimination laws.2'
Federal law creates a period of market
exclusivity that provides an innovative pharmaceutical manufacturer with an
opportunity to recover capital costs associated with research and
development (R&D).2 38 Market exclusivity is a statutory provision granting
an applicant of a New Drug Application (NDA) exclusive marketing rights
by the United States Food and Drug Administration (FDA) upon approval of
a drug.23 9 These laws promote a balance between new drug innovation and
generic drug competition, and between pharmaceutical companies' dual
goals.24 °

Since capital costs for manufacturing drugs tend to be extremely high,
many pharmaceutical companies use the high costs as justification for setting

http://www.investopedia.com/ask/answers/013015/how-does-marginal-cost-productionrelate-economies-scale.asp (stating that marginal cost is the cost of producing one more
additional unit of a good).
234. See Winegarden, supra note 231 at 5, 18-23 (stating that R&D expenses are very
high and also have a high failure rate).
235. Lawrence Perkins, PharmaceuticalCompanies Must Make Decisions Based on
Profit, 175 W. J. MED. 422, 423 (2001); David Shaywitz, What's Holding Back Cures? Our
Collective Ignorance (And No, Not a Pharma Conspiracy), FORBES (May 10, 2013),
https://www.forbes.com/sites/davidshaywitz/2013/05/10/
whats-holding-back-cures-ourcollective-ignorance-and-no-not-a-pharma-conspiracy /#7a44ff84236f.
236. Annetine C. Gelijns & Ethan A. Halm, The Changing Economics of Medical
Technology,
THE
INST.
OF
MED.
41
(1991),
https://www.ncbi.nlm.nih.govbooks/NBK234308/pdf/BookshelfNBK234308.pdf.
237. Melody Peterson, Here's Why Drug Prices Rise Even When There's Plenty of

Competition,L.A. TIMES (Sept. 1, 2016) http://www.latimes.com/business/la-fi-mylan-pricehikes-20160830-snap-story.html.
238. See generally,Winegarden, supra note 231.
239. 21 C.F.R. § 314.108 (2014).
240. Frequently Asked Questions on Patents & Exclusivity, U.S. FOOD & DRUG

https://www.fda.gov/drugs/developmentapprovalprocess/ucm079031.htm
5, 2016); see Winegarden, supra note 231, at 5.
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high prices.24 1 After all, pharmaceutical innovation is expensive. 242 The New
York University Stern School of Business calculated a weighted average cost
of capital (WACC) for the pharmaceutical industry, finding that for
innovative pharmaceutical companies, the WACC is significantly higher than
the average WACC for other types of businesses. 4 3 This data indicates the
greater risks involved in developing innovative pharmaceuticals compared to
risks incurred by other types of manufacturing companies. 2 " Further,
economists estimate that the total capital costs incurred by innovative
pharmaceutical companies with a $5.5 billion R&D budget over a fifteenyear period are around $17.2 billion, the total capital costs incurred by a $2.0
billion R&D budget is $6.2 billion, and the total capital costs of a $500
million R&D budget is $1.6 billion. 4 5 These staggering numbers account for
the time and risk involved in developing a new drug. 246
Each patented pharmaceutical's annual cost of capital is approximately
uh a successful drug must earn $1.5 billion in
$1.5 billion per year. 247A
As such,
revenue each year to recover the capital costs for the company's R&D
expenditures.24 8 Furthermore, most drug innovations often fail, causing
companies focused on pharmaceutical development to lose a significant
amount of money.249 It is far less costly to produce a drug that has already
been invented and FDA approved, than to produce a drug during its clinical
trial phase before the efficacy and safety of the drug is clearly understood.250
Further complicating this economic quandary, only two of ten medicines
proven to be efficacious and safe is actually profitable enough to return an
income stream greater than the cost of their R&D. 2 ' A pharmaceutical
company's opportunity to recoup capital costs expires upon the expiration of
its patent, at which point, generic competitors hit the market with lower
prices. 2 Without the current structure of the U.S. patent system, many
innovative pharmaceutical companies would potentially lose the opportunity
to fully recoup capital costs. 25 3 Pharmaceutical innovation is inextricably
241.

Sydney Lupkin, 5 Reasons Prescription Drug Prices Are So High in the U.S.,

MONEY http://time.com/money/4462919/prescription-drug-prices-too-high/ (last visited Dec.
5, 2017).
242.
See Winegarden, supra note 231, at 18.
243.
Id. at 20.

244.
245.
246.

Id.
Id.
Id.

247.

Id. at 7.

248.

Id.

249.
250.
251.
252.
253.

Id. at 6.

Id.
Id.
Id.
Id.

at 22-23.
at 5.
at 7.
at 5.
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linked to an innovative pharmaceutical company's ability to recoup its costs
of capital; if each innovator must immediately compete with generics
manufactured by companies that avoided large capital costs, such innovation
is impossible. 4
Evidence concludes that the long-term value of Sovaldi outweighs the
value of its competitors,255 and the price of Sovaldi lends to further R&D and
innovation to benefit more patients over time.2 56 Stifling future R&D by
immediately providing a lower priced curative, would cause more harm to
HCV patients than good.15' Hence, the need for R&D is essential to
improving the health of tomorrow's patients.
On the other hand, policy makers opposing Gilead, 8 such as Democratic
Senator Ron Wyden and Republican Senator Chuck Grassley, argue that the
company cannot use high capital costs to justify the price of Sovaldi,259
because rather than creating the drug, Gilead bought out Pharmassett for
$11.2 billion, 260 and in its first quarter on the market, Gilead astonishingly
recouped more than $2 billion. 26 1 This contingent further contends that by
the time Gilead's patent expires, it will likely have one of the highest profit
margins for any pharmaceutical company in U.S. history.262 However, that
argument fails to consider other costs associated with bringing a drug to
market. For example, although Gilead did not develop Sovaldi, it entered
Sovaldi into costly Phase III clinical trials to obtain FDA approval. 263 This

254.
Id. at 6-7.
255.
Gilead's All-Genotype Hep C Drug Boasts Excellent Cure Rates, supra note 206;
Epclusa: The Newest Hepatitis C Treatment, supranote 206.

256.
See Winegarden, supra note 231 at 5, 18-23; Perkins, supra note 235, at 423;
Shaywitz, supra note 235.
257. See Winegarden, supra note 231, at 5.
258. UNITED STATES SENATE COMMITTEE ON FINANCE, LETTER TO JOHN C. MARTIN, CEO,
GILEAD SCIENCES, INC. (2014).
259.

Alex Keown, New Report Accuses Gilead (GILD) of Putting Profit Ahead of

Patients, BIOSPACE (Dec. 2, 2015, 5:54 PM) http://www.biospace.com/News/new-reportaccuses-gilead-of-putting-profit-ahead/401541 (citing Senator Ron Wyden and Senator Chuck
Grassley as opponents of Gilead, who believe Gilead cannot justify the high prices of its drugs
by using research and development or the multi-billion-dollar acquisition of Pharmasset, Inc.).
260.

Paris, et al., New Health Technologies: ManagingAccess, Value and Sustainability,

FOR
ECON.
CO-OPERATION
&
http://g8fiplkplyr33r3krz5b97dl .wpengine.netdna-cdn.com/wpcontentluploads/2017/01/OECD-on-new-drugs-and-pricing.pdf.
ORG.

261.

DEV.

93

(2017),

The Top 10 Emerging Blockbusters: Billion Dollar Molecules, C&EN SUPPLEMENT

10 (2014), https://cen.acs.org/content/dam/cen/supplements/CEN-supplement092014.pdf.
262.

Mark Terry, A Look at the 5 Most ProfitableBiopharma Companies, BIOSPACE (Jun.

20,
2017),
http://www.biospace.com/News/a-look-at-the-5-most-profitablebiopharma/460555 (showing that Gilead already has one of the highest profit margins of any
company).
263.
Alexander Gaffney, Report: Phase III Clinical Trials Behind Increase in the Cost of
Pharmaceuticals, REG. AFFS. PROFS. Soc'Y (Apr. 25, 2012), http://www.raps.org/focus-
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highly regulated process likely cost Gilead hundreds of millions of dollars.2 64
Other costs likely abound. Although Gilead's manufacturing and other
expenditures associated with Sovaldi are generally unknown, 265 one may
project the basic economic costs that apply to all pharmaceutical companies
onto Gilead.266 It is estimated that only one in every 10,000 new compounds
will be FDA approved, and out of those, five of them will make enough profit
to justify the investment.2 6
If development of new medicine costs
approximately $5 billion, this amount begins to multiply when also
considering the cost of the drugs which fail mid-development, or the cost of
developing multiple drugs. 268 Gilead did not develop Sovaldi, but Gilead
represents an innovative company trying to create new antiviral
27 °
medications. 2 61 While, it takes close to fifteen years to develop a new drug,
a pharmaceutical company's revenue may only derive from any drug it
already invented over that time period. 27 1 As development costs grow more
expensive every year, pharmaceutical companies like Gilead will continue to
rely on high revenues to conduct R&D.2 2
C. Gilead's Willingness to Lower Drug Prices Overseas,and Active
Participationin Sovaldi-DistributingCharities,Provide Evidence that

online/news/news-article-view/article/1 359/.
264.
Id.
265.
Stephen Barlas, The Clinical Trial Model is Up for Review, NAT'L CTR. FOR
BIOTECHNOLOGY
INFO.,
(Oct.
29,
2014),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189694/.
266. Economicsfor PharmaceuticalManagement,MGMT. SC. FOR HEALTH 1, 14 (2012),
https://www.msh.org/sites/msh.org/files/mds3-chIO-pharmoeconomics-mar2012.pdf
(showing general economic costs that apply to pharmaceutical companies).
267.
Timothy O'Shea, The Unusual Discovery of 10 Commonly PrescribedMedications:
Part
1,
PHARMACY
TIMES
(Sept.
11,
2017),
http://www.pharmacytimes.com/contributor/timothy-o-shea/2017/06/the-unusual-discoveryof- 10-commonly-prescribed-medications-part- 1.
268.
Matthew Herper, The Cost of Creating a New Drug Now $5 Billion, Pushing Big
Pharma
to
Change,
FORBES
(Aug.
11,
2013),
https://www.forbes.com/sites/matthewherper/2013/08/1 1/how-the-staggering-cost-ofinventing-new-drugs-is-shaping-the-future-of-medicine/#789 l0eeel 3c3.
269.
Avik Roy, The Sovaldi Tax: Gilead Can't Justify the Price It's Asking for Hepatitis
C
Therapy,
FORBES
(Jun.
17,
2014),
https://www.forbes.com/sites/theapothecary/2014/06/17/the-sovaldi-tax-gilead-cant-justifythe-price-its-asking-americans-to-pay/#549777555670.
270.
Roxane Nelson, Why Are Drug Costs So High In The United States?, MEDSCAPE
(Sept. 11, 2017), http://www.medscape.com/viewarticle/835182#vp-8.
271.
Ransdell Pierson, Big Pharmais Innovating by Selling Old Drugs and Making a
lot of Money in the Process,Bus. INSIDER (May 4, 2014), http://www.businessinsider.com/rbig-pharma-stands-to-profit-by-cleaning-out-its-medicine-chests-2014-04.
272.
Herper, supra note 268.
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Gilead'sBehavior was not selfishly motivated

Gilead demonstrated an interest in helping as many HCV patients as
possible through its philanthropic endeavors.3 Opponents of Gilead argue
that low prices of Sovaldi in foreign countries demonstrates that Gilead set
the price of Sovaldi unconscionably high in the U.S. 274 However, those
arguments ignore the circumstances under which pharmaceuticals can be
priced so low in countries such as Egypt and India. 2
Gilead's marketing
26
decisions reflect the differing laws among nations, 7 and the lower prices
offered in third world countries may, in part, be attributed to Gilead's
generosity. 27
Turning to two instances of price differentiation, a twelve-week treatment
regimen of Sovaldi costs $57,000 in the United Kingdom and $55,000 in
Canada.2 78 This discrepancy in pricing may be explained by the significantly
different laws between the United States and these two countries.2
In the
U.S., for example, Medicare is not legally permitted to negotiate with drug
manufacturers. 20 This is highlighted in Part IV B of this paper. The U.K.
and Canada both operate single-payer health care, under which the
government can negotiate drug prices directly with foreign manufacturers to
281
attain discounted prices that it provides to its citizens at a uniform cost.
Furthermore, the United Kingdom's National Institute for Health and Care
Excellence (NICE) evaluates every new drug and decides whether the U.K.'s
healthcare system should pay for it. In 2013, NICE defended Gilead,

273. Maggie Fick & Ben Hirschler, Gilead Offers Egypt New Hepatitis C Drug at 99
Percent Discount, REUTERS (Mar. 21, 2014), http://www.reuters.com/article/us-hepatitisegypt-gilead-sciences/gilead-offers-egypt-new-hepatitis-c-drug-at-99-percent-discountidUSBREA2KiVF20140321(discussing Gilead's offer to supply Egypt at 99% discount to the
US price).
274. Roy, supra note 269.
275. Fick & Hirshler, supra note 273; John LaMatinna, When it Comes To Abusive Drug
Pricing, Don't Confuse Shkreli for Hep C Drugs, FORBES (July 19, 2017),

https ://www.forbes.com/sites/j ohnlamattina
/2017/07/19/when-it-comes-to-abusive-drugpricing-dont-confuse-shkreli-with-hep-c-drugs/#3defla34af68.
276. Frederick M. Abbott, Excessive PharmaceuticalPrices and Competition Law:
DoctrinalDevelopment to Protect Public Health, 6 U.C. IRVINE L. REv. 281, 283-85 (2016).
277. LaMatinna, supra note 275 (discussing Gilead should be congratulated for lowering
prices in areas with a high rate of Hep C infections like India and Egypt).
278. LaMatinna, supra note 275; Sovaldi: Who's to Blame, supra note 24.
279.

Aaron E. Carroll & Austin Frakt, The Best Health Care System in the World: Which
Would
You
Pick?,
N.Y.
TIMES
(Sept.
18,
2017),
https://www.nytimes.com/interactive/2017/09/18/upshot/best-health-care-system-country-

One

bracket.html.
280. Michael Hiltzik, Allowing Medicare to Negotiate Drug Prices is a PopularSolution
to Healthcare Costs. But it May Not Work, L.A. TIMES (Jan. 11, 2017),
http://www.latimes.com/business/hiltzik/la-fi-hiltzik-medicaire-negotiate-201701
story.html.
281. Sovaldi: Who's to Blame, supra 24; Fick & Hirschler, supra note 273.
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"Charging less for Sovaldi in the U.K. was reasonable because it is consistent
with differential pricing and with the rules established by NICE."2'82
Meanwhile, the U.S. spends more money on healthcare, and plays host to
significantly more R&D for novel drugs, than anywhere else in the world.283
As a result, foreign countries with universal healthcare systems largely
escape the capital costs, manufacturing costs, malpractice litigation, or any
of the extremely high costs associated with developing a new drug in the
2 84

U.S.

Finally, Gilead's domestic and international efforts to ensure access to
Sovaldi challenge opponents' characterization of Gilead as an unethical
entity. Gilead has historically made its products available in impoverished
countries.
In 2011, Gilead became the first pharmaceutical company to
form a deal with the United Nations-backed organization, Medicines Patent
Pool (MPP), founded with the purpose of increasing access to HIV
treatment.286 In order for inexpensive versions of Gilead's HIV therapies to
be manufactured and distributed in poor countries, Gilead donated four of its
HIV-therapy patents to MPP. 287 Moreover, in 2016, it was revealed that
Gilead provides the country of Georgia with Sovaldi at little to no cost after
Georgia's Health Minister asked Gilead for help in eradicating HCV in
Georgia altogether.288 In September 2014, Gilead announced that it granted
a license to several Indian companies to produce a less expensive, generic
289
version of Sovaldi and Harvoni to distribute in 112 developing countries.
Gilead also proved its devotion to ensuring access to Sovaldi in resourcelimited settings in the United States. 29 ' The company developed a Hepatitis
282.
Sovaldi: Who's to Blame, supranote 24.
283.
Susan Brink, What Country Spends the Most (and Least) On Health Care Per
Person?,
NPR
(Sept.
11,
2017),

http://www.npr.org/sections/goatsandsoda/2017/04/20/524774195/what-country-spends-themost-and-least-on-health-care-per-person; Biopharmaceutical Spotlight, INT'L TRADE
ADMIN.,

https://www.selectusa.gov/pharmaceutical-and-biotech-industries-united-states

(last

visited Dec. 5, 2017).
284. BiopharmaceuticalSpotlight, supra note 283.
285.
Sovaldi: Who's to Blame, supra note 24; GileadAnnounces New Agreement with
Medicines Patent Poolfor Access to Medicines in Developing World Countries, GILEAD SCI,
INC. (July 24, 2014), http://www.gilead.com/news/press-releases/2014/7/gilead-announces-

new-agreement-with-medicines-patent-pool-for-access-to-medicines-in-developing-worldcountries.
286.
Sovaldi: Who's to Blame, supra note 24; GileadAnnounces New Agreement, supra
note 285.
287. Sovaldi: Who's to Blame, supranote 24.
288. Bloomberg: GileadProvides Georgia with Sovaldi for Free, Claiming Virus Could
be Eliminated in 10 Years or Less, Bus. POL. INSIGHTS (Mar. 7, 2016),
http:/[bpi.ge/index.php/bloomberg-gilead-provides-georgia-with-sovaldi-for-free-claimingvirus-could-be-eliminated-in- 10-years-or-less/?lang=en.
289.

290.
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C treatment access program, that focuses on providing Sovaldi in countries
with the greatest HCV burden.29 1 Gilead even created the Support Path
Patient Assistance Program in the U.S., which provides Sovaldi and Havoni
at no charge for eligible patients with no other insurance options.292
Additionally, the Sovaldi and Harvoni Co-Pay Coupon Program is expected
to provide co-pay assistance to eligible patients with private insurance who
need help paying for out-of-pocket treatment costs. 293 Through this program,
HCV patients will pay no more than a $5 co-pay.294 Such patient assistant
programs evidence that Gilead has the best interest of HCV patients in mind,
wants to use a portion of the recoupment costs to assist impoverished patients
across the world, and has not violated the ethical principles of beneficence
and justice. 295
CONCLUSION

The discovery of Sovaldi is a medical breakthrough and is considered a
clinical cure for treating HCV genotype 1 without peg-IFR.296 However,
Sovaldi's high price at $1,000 per pill makes it subject to ethical controversy.
Americans do not have a fundamental or inalienable right to Sovaldi
treatment. Therefore, although all HCV patients technically have access to
the drug, prescriptive barriers, and barriers caused by health insurance
companies, make accessing Sovaldi difficult for a large number of HCV
patients. Sufficient evidence suggests that Gilead's pricing motivation was
ethically sound because the drug's superior quality justifies its price and U.S.
law prohibits drug pricing negotiations between the federal government and
pharmaceutical companies. Moreover, there is evidence that Gilead's price
setting behavior was merely a reflection of the U.S. patent system, which
allows innovative pharmaceutical companies to prevent short-run
competition on newly developed drugs against generics as a way to later

Treatment of Chronic Hepatitis, GILEAD (Dec. 6, 2013), http://www.gilead.com/news/press-
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recoup the millions of dollars they spend during the drug development
process. Lastly, Gilead's efforts to lower the price of Sovaldi in developing
countries, and participation in charities distributing Sovaldi to low income
Americans, provide further evidence that Gilead's pricing decisions were not
unethically motivated.
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